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Cellular membranes contain a vast variety of proteins, which are practically required for every 
vital mechanism, such as selective transportation of ions and organic molecules, cell-cell 
recognition and signal transduction.[1] Nowadays, the major concern in life science is to gather 
an overview about the thermodynamics and kinetics that govern the native folding and 
aggregational behavior of these proteins. Artificially folded polymers, or foldamers, have 
attracted the interest of many research groups since they showed the potential for 
considerable versatilityin biological functions akin to natural proteins.[2] Thus, the prudent 
preorganization and refinement of such molecules can shed light on the molecular forces that 
control the structural features of membrane proteins and thereby, explore the correlation 
between their conformational stability and biological activity.  
In particular, β-peptides have recently been used as very promising peptide mimics with 
interesting conformational and functional propensities. These non-biological polymers are 
stable towards enzymatic degradation and they can fold into compact multihelical structures 
including the 14- and the 12-helix.[3] Generally, introducing non-covalent interactions, such as 
hydrogen bonds and Vander Waals forces via interhelical side chains can enhance the three-
dimensional stability of proteins. In this regard, β-peptides have been largely utilized as 
suitable folding patterns to provide information about self-assembly processes.[4-6] 
Based on this concept, the main goal of this study is to understand the dynamics and the 
molecular interactions of transmembrane peptides using the most common β-peptide helices, 
the 14- and the 12-helix, as scaffolds to introduce polar residues across turns of the helix. This 
preorganization is expected to strongly promote self-assembly of these helices within 
membranes by means of interhelical forces. Thus, the architecture of the β-peptides used in 
this study was based on the choice of amino acids that can preferentially induce the formation 
of stable 14- and 12-helices. Subsequently, one side of these helices would be functionalized 
with one, two and three polar β3-glutamine residues respectively to reinforce helix-helix 





As a first step, the synthetic route of β-peptides containing a large amount of hydrophobic β-
residues will be developed usingmanual microwave-assisted Fmoc-solid phase peptide 
synthesis (SPPS). Then, the ability of each of these β-peptides to adopt a rigid and a specific 
secondary structure either in solution or within large unilamellar vesicles (LUVs) composed of 
POPC will be monitored by CD spectroscopy. The membrane insertion of all the peptide barrel 
will be confirmed by virtue of tryptophan fluorescence of the β3-Trp introduced near the end 
of the sequences.  
Additionally, the self-assembly process of these transmembrane helices inside POPC LUVs will 
be determined using Förster Resonance Energy Transfer (FRET). For this purpose, a donor-
acceptor pair will be covalently attached to all the helices in order to generate their 
corresponding fluorescent analogues.  
The backbone of the 14- and the 12-helix vary widely in terms of their conformational 
properties. Based on this notion, it is expected that the self-assembly of these two helices 
might vary as well according to their propensities to adopt discrete types of assemblies. 
Therefrom, the dissimilarity (or similarity) of these helices to arrange into different three-
dimensional structures will be examined.  
As a last step, to investigate the possibility of higher aggregation, the conformational features 
of the peptide barrel will be used by introducing polar residues across two sides of the helix. 
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1 Biological Membranes 
1.1 Membrane Lipids 
Biological membranes are distinguished by a heterogeneous assembly, which broadly appears 
in aspects like the wide variety of their components, lateral organization, topology, and the 
conformation of proteins and lipids.[7] In 1935, Danielli et al. proposed the first membrane 
model including proteins and they postulated that a protein layer is tightly linked to the polar 
head groups of the lipids, composing together cell membranes.[8] After more than three 
decades, Singer et al. provided a more detailed conception called fluid mosaic model, in which 
the biological membranes are formed by an organized environment of lipids in a fluid state 
incorporating globular assembling of proteins and glycol-proteins.[9] After the discovery of this 
phase of separation in the plane of membrane, more efforts havebeen made in the last 
decades to explore the functions and the composition of cell membranes as well as to develop 
new technologies for revealing the lateral heterogeneities of cells. Nowadays, biological 
membranes are believed to play an essential role in cellular protection and also in the control 
and transport of nutrients. 
While lipids provide the most plentiful type of macromolecules present in membranes, 
proteins carry out a wide array of specific functions, including selective transport of molecules 
and cell-cell recognition. There are three major classes of membrane lipids: 
phosphoglycerides, sphingolipids and sterols. These three types of lipids are featured by a 
wide variety in their hydrophilic headgroups and diverse fatty acid compositions. Both, 
phosphoglycerides and sphingolipids, can be combined as one class calledphospholipids. The 
latter are classical type of membrane lipids with an amphipathic character due to the presence 
of both, polar head groups and apolar hydrocarbon chains, forming together a stable barrier 
between the two aqueous compartments, which are the inside and outside of the cell 
membrane. Phospholipids are widely used to obtain model systems for biophysical 
applications to study biological and artificial molecular species in the membrane 
environment.In general, the lipids can be synthesized or extracted from plant- or animal-





Phospholipidscontain a head group, a glycerol backbone and two fatty acid chains or the so-
called “tails” (Figure 1.1). One oxygen group of the phosphoric acid might be esterified, giving 
a rise to a variety of other organic molecules including glycerol (PG), choline (PC), 
ethanolamine (PE), serine (PS) or inositol (PI). However, PC and PE are considered as the most 
used model lipids to produce liposomes since they are the most abundant phosphatides in 
plants and animals.[11]  
 
 
Figure 1.1: Chemical, three-dimensional and schematic illustrationof L-α-phosphatidylcholine (HSPC).[22] 
 
The polar head groups of the outer leaflet extend outward the hydrophilic environment and 
can contain either charged or uncharged polar moieties. In most natural phospholipids, 
the fatty acid tails extend inward the cell and usually consist of about 14-24 carbon atoms with 
variations in length. One tail of the lipid may have one or more cis-double bonds thatinsert 
kinks into the hydrocarbon chains and render them difficult to pack together, leading to an 
alteration in membrane fluidity. The two acyl chains of the lipids are hydrophobic and solely 
interact with adjacent molecules viaVan der Waals interactions. They are linked to the glycerol 
or sphingosine backbones via ester bonds.  
There are two general merits of phospholipid bilayers that are critical to membrane 




impermeable to water-soluble substances, including ions and most biological species. This 
characteristic makes the structure of the phospholipidsin charge of the basic function of 
membranes as barriers between two aqueous compartments. Second, the long acyl chains of 
the fatty acids move freely in the internal part of the membrane, so the inner-membrane itself 
is a viscous fluid and flexible. When immersed in an aqueous environment, lipid molecules can 
spontaneously self-assemble into specifically ordered lyotropic liquid-crystalline phases to 
bury their hydrophobic tails in the interior and expose their hydrophilic heads to the aqueous 
medium. Generally, there are nomurous intrinsic factors that control the shape of the 
resulting phospholipid-based structures like the nature and the size of the lipid head group, 
the length and degree of unsaturation of the hydrocarbon chains and the extrinsic factors like 
the temperature, pH and the concentration.[13,14]There are many examples of lipid-based 
structures such as, monolayers, micelles (Figure 1.2a), reverse micelles (Figure 1.2b), bilayers 
(Figure 1.2d) and hexagonal phases (Figure 1.2e). 
 
 
Figure 1.2: Common lamellar and non-lamellar packing arrangements of lipids in aqueous environment. (a) 




Most lipids that form spherical micelles have charged head groups leading to a large head 
group area. In contrast, amphiphiles with small head group area or bulky hydrocarbon chains 
cannot fit into such small aggregates to pack into micellar structure but, instead form bilayers. 
Under certain conditions, the formation of curved bilayers (vesicles) becomes more favorable 
than the formation of infinite planar lipid bilayers. This arises from the elimination of the 
energetically unfavorable edges of the vesicle at a finite rather than infinite number of 
aggregation, which is also entropically favored.[16,17] Thus, as long as lipids are in a closed 
spherical bilayer, they can maintain areas at their optimal values, which means that vesicles 
would be the preferred spatial orientation in this case. In addition, lipid bilayers are considered 
as the major building blocks of biological membranes which, together with membrane 
proteins and cholesterol, control the shape of the cell and many other functions like storage 
of compounds, ions transport, cell fusion and metabolism.[15] 
In cells, lipids are featured by various spatial arrangement and motional freedom by adopting 
different fluid and solid phases with respect to the surrounding environment. Moreover, one 
of the most important characteristics of cells that allows a given substance to pass through 
the membrane only with selective permeability is the capacity of the lipid bilayer to keep 
various environments between external and internal region.[15,18] 
As mentioned previously, the degree of fatty acid saturation affects the mobility of lipids. 
However, the temperature is another factor that can highly influence their fluidity within the 
bilayer.[19] When the temperature changes, the physical state of the phospholipid bilayer 
changes as well from a two-dimensional rigid crystalline (or gel) to a liquid state or vice-versa. 
This change of state is called a phase transition. There are several factors that directly 
influence the phase transition temperature (Tm) including hydrocarbon length, unsaturation, 
charge and head group species.[20]For instance, as the hydrocarbon length increases, Van der 
Waals interactions become stronger and the membrane-permeability decreases, requiring 
more energy to disrupt the ordered packing and thereby, the Tm increases.[21] Conversely, 
introducing a cis-double bond into the acyl group requires much lower temperatures to induce 
an ordered packing arrangement.[18]  
As indicated in Figure 1.3, at a temperature below Tm, phospholipids exist in a gel phase and 
present low fluidity and low permeability. As a result, hydrophobic tails in the interior of the 
lipid bilayer pack together more tightly. At a temperature above Tm, the phospholipids are 




permeability of the lipid bilayer, increase slightly. This phenomenon is attributed to the 




Figure 1.3: Schematic representation of the influence of temperature on phospholipid bilayer fluidity and 
permeability.[22] 
 
1.2 Membrane Proteins 
Biological membranes contain mainly phospholipids and proteins, conferring them unique 
physical and chemical properties. Membrane proteins contribute to diverse and critical 
cellular functions such as cell adhesion, energy transduction, signaling, cell recognition and 
transport of ions and other small molecules.[23] Protein complexes are stabilized within the 
cell membrane by various chemical forces, such as hydrogen bonds, hydrophobic, electrostatic 
and Van der Waals forces.[1,24]This mostly depends on the local dielectric environment of 
protein atoms, which means by way of spatial arrangement of proteins in membranes.[25,26] 
 
1.2.1 Protein-Lipid Interactions 
To ensure the solubility of proteins in membranes, polarity of the lipid phase should match 
the polarity of the embedded proteins. In this regard, the membrane fluidity must be strictly 
adjusted in various cells and in various environmental conditions by regulating the lipid 




can be maintained even at highly anisotropic lipid environments.[27] The complement of 
proteins linked to a membrane varies depending on the cell type and subcellular location. 
Generally, membrane proteins can be classified into two broad categories, integral proteins 
and peripheral proteins.[28] This classification is mainly based on the proteininteractions and 
functions within the membrane.  
While integral proteins cross the entire phospholipid bilayer with structures that embed from 
one side of the membrane to the other side, peripheral proteins are bound indirectly to 
the membrane  by interacting with integral membrane proteins or directly by interacting 
with polar head groups of lipids. Integral membrane proteins present a large part of biological 
membranes ranging from 20-80%.[29] The transmembrane-spanning domains of these special 
proteins contain a straight or tilted stretch of about20 amino acids with hydrophobic side 
chains that interact with the inner part of the membrane followed by distinct clusters of 
aromatic and charged residues on both sides that have a specific affinity to the membrane-
water interface. α-Helices, multiple β-strands and β-helices are the most conspicuous 
membrane-spanning domains known to date that can fulfill the requirementsneed for a 
hydrogen bond prospect of a polypeptide main chain to be saturated inside a hydrophobic 
environment. The α-helical proteins are abundantly found by approximately 25-30% of the 
genes of all sequenced organisms in all types of cellular and intracellular membranes.[31] 
Whereas, the β-barrels are encoded by less than 3% of bacterial genes and mainly exist in 
outer membranes of bacteria, mitochondria and chloroplasts.[31,32] Besides, single- and 
double-stranded β-helices are known from membrane polypeptides with alternating L- and D-
residues like gramicidin A, B and C.[28] 
In order to obtain detailed information about the interactions between proteins and lipid 
bilayer, relatively simple model membranes have been used, in which structural parameters 
can be systematically altered. Thus, useful information derived from these model systems 
depend critically on the choice of proteins and lipid compositions. Indeed, there are many 
examples of α-helical peptides that have been designed to gain insight into adaptations of 
proteins to their environmental membranes. Especially those proposed by Killian et al. 
consisting of sequences with alternating alanine and leucine residues as hydrophobic stretch 
flanked by either polar lysine residues (KALP peptides) or tryptophan residues (WALP 
peptides).[34,7] These synthetic peptides have been applied to show the direct influence on the 




precisely explore the effect of altering their hydrophobic length relative to the bilayer 
thickness. These phenomena are readily explained by the concept of hydrophobic mismatch 
arising from a difference between the hydrophobic thickness of lipid membranes and the 
length of transmembrane protein segments. Also, hydrophobic mismatch is thought to play 
an important factor controlling membrane protein insertion and folding,[35] protein activity[36] 
and aggregation.[37] Many experimental and theoretical studies have revealed that two types 
of hydrophobic mismatch can occur: first, a positive mismatch, in which the hydrophobic part 
of a transmembrane protein is too large to match the hydrophobic bilayer thickness 
andsecond, a negative mismatch, in which the length of the peptide segment is shorter than 
the hydrophobic bilayer thickness.[23,35] As a result of these two cases, the peptides as well as 
the lipid bilayer may give different responses to relieve the energetic constraints imposed by 
the hydrophobic mismatch. From the lipid side, the thickness of the overall bilayer might be 
affected with concomitant alterations in phase properties, or a letarl phase segregation can 
be promoted.[37,38] On the protein side, the elastic energy of mismatch may favor 
aggregation,[39,40] lateral sorting and/or structural reorganizations.[41,42] The plausible 
mechanisms that can be adopted by either proteins and lipid bilayers are schematically 
depicted in Figure 1.4.  
Thus, in case of a positive hydrophobic mismatch (Figure 1.4, left), the proteins might 
oligomerize in the membrane to minimize the exposed hydrophobic area, they could tilt to 
reduce their effective hydrophobic length or vary the backbone conformation. Lipids in turn 
could modulate the bilayer thickness by stretching their acyl chains or even assemble into 
another type of aggregates by disrupting the bilayer organization.  
In case of a negative hydrophobic mismatch (Figure 1.4, right), proteins could aggregate or 
change their backbone conformation. Furthermore, a deformation of their side chain 
orientation can occur. In addition, peptides with insufficient length of hydrophobic stretch 
might not incorporate into the membrane but, instead tend to localize on the lipid surface. 
Alternatively, lipids could reduce the effective bilayer thickness by disrupting the bilayer 






Figure 1.4: Schematic illustration of some possible consequences arising from positive hydrophobic mismatch 
(left) and negative hydrophobic mismatch (right).[35] 
 
Interestingly, it has been indicated that a difference of about 7 Å for a positive hydrophobic 
mismatch and more than 13 Å for a negative hydrophobic mismatch could be tolerated, 
presumably, because of the alternative possibility of tilting.[35] Such a helix tilt can significantly 







1.2.2 Protein-Protein Interactions 
Helix-helix interactions are intrinsic to virtually every cellular process. In nature, 80% of 
proteins exist as oligomeric complexes to perform their biochemical functions, rather than 
remaining as individual species.[43] Based on energetic considerations, the possible driving 
forces for interactions between transmembrane helices are packing effects, such as 
interhelical polar interactions including hydrogen bonds and ion pairs as well as Van der Waals 
interactions between closely packed helices.[44] A study proposed by Popot and Engelman and 
then elaborated by White and coworkers has revealed that the process of protein assembly 
within the membrane can be simplified in terms of two energetically distinct stages, the so-
called “two-stage model” (Figure 1.5).[45,46] 
 
 
Figure 1.5: Example of the two-state model of membrane protein folding using bacteriorhodopsin from 
Halobacterium salinarum (231 residues). In the first stage, the preformed helix inserts into the bilayer followed 





In the first stage, the protein is transferred from water to the apolar region of the bilayer 
driven by the hydrophobicity of its apolar side chains. Whereas, aromatic and positively 
charged residues tend to localize near the bilayer head group regions and thereby, contribute 
to the appropriate orientation of the protein within the biological membrane. After inserting 
in the membrane environment, the second stage consists of stabilizing the protein’s helical 
conformation by satisfying its backbone energy via amide-carbonyl hydrogen bonds. Then, the 
protein can be able to assemble through the coalescence of helices to form the tightly native 
tertiary structure. In this stage, the possible diffusion of the helices within the plane of the 
membrane bilayer will be limited due to the presence of links between the helices meaning 
that the unfavorable entropic term in the free energy of association isminimized, which is for 
example the case of disulfide bridges in soluble proteins.[48] 
Although this two-stage model provides valuable conceptual frameworks for understanding 
the actual kinetic process of protein insertion and folding as it occurs in vivo, the features that 
govern the subsequent association of the inserted helices are controversial and remain poorly 
understood.[49] Thus, in recent years numorous simple transmembrane protein model 
segments have been developed to address the general properties that promote helix-helix 
association, such as the presence of apolar, charged or aromatic residues.[50,51]Compared with 
the composition of proteins in general, the apolar side chain residues in transmembrane α-
helices exhibit the most prevalent species and play an essential role for function, 
conformational specificity and thermodynamic stability of the entire protein.[52,53] To this end, 
several examples displaying the role of hydrophobic side chain residues in a transmembrane 
domain have been reported. Interestingly, Engelman and his group have explored the primary 
GxxxG motif[47] as a model transmembrane helix composed of solely apolar and small amino 
acids. This discovery has steered attention to the importance of Van der Waalsinteractions in 
transmembrane protein folding and has also enabled understanding of the specific 
dimerization of the whole motif family, which includes the SxxxS,[54] SxxxSxxxG[55] or FxxGxxxG 
motifs.[56] 
Beside the fact that buried apolar residues appear to relatively provide a sufficient force for 
proteins folding, polar motifs are expected to driveassociation in membranes. The low-
dielectric environment displayed by the hydrocarbon core of a lipid bilayer conveniently 
results in strong electrostatic interactions.[1] As a result, the formation of a hydrogen bond 




proteins since in the hydrophobic region of the lipid membrane, dehydration of the two 
interacting groups is not required to form a stable hydrogen bonding.[57]Substantially, Hu and 
coworkers have found out that placing the polar Asn residues at four buried a positions in a 
two-stranded coiled coil seems to contribute to conformationally stabilizing the coiled coil 
peptides viaformation of hydrogen bond forces between Asn residues side chains.[58] Similarly, 
Engelman et al. as well as Degrado et al. havedemonstrated that other polar motifs, such as  
Asp, Glu, Gln or His appear to be fundamental for folding, proton translocation activity and 
other biological functions.[50,59] 
Aromatic side chains in turn can be essential for Van der Waals forces, hydrophobic and weak 
polar interactions.[60,61] In fact, Phe residues can enhance transmembrane domain interactions 
when it is placed at position i-3 of a GXXXG motif.[56]Furthermore, it has been found that Trp 
and Tyr prefer to localize at the termini of many membrane proteins close to the hydrophobic-
hydrophilic region, where they are thought to vertically anchor the protein in the lipid 
bilayerby interacting with the membrane head groups.[55,62] 
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2 Artificially Folded Molecular Structures 
2.1 Foldamers 
In nature biological macromolecules (mainly proteins and nucleic acids) are in charge of 
carrying out sophisticated chemical tasks, such as catalysis, directed flow of electrons, specific 
binding and controlled crystallization of inorganic phases.[3]In particular, proteins are 
considered as very  interesting biological polymers since they play a key role in many biological 
processes and have a strong tendency to adopt specific and tight conformations. The process 






Figure 2.1: The four recognized levels of protein structures including A) primary, B) secondary, C) tertiary and D) 
quaternary structures. (Image modified from OpenStax Biology’s by National Human Genome Research 
Institute). 
 
Primary structure: the linear sequence of amino acids linked together by peptide bonds, 
forming a polypeptide. 
Secondary structure:  locally folded structure formed within a polypeptide due to interactions 
between atoms of the backbone resulting in a defined directionality in all cases. The most 
common types of secondary structures are the α-helix and β-sheet.  
Tertiary structure: the overall three-dimensional structure of a polypeptide that arises from 
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include a much broader range of intermolecular contacts such as disulfide bonds, hydrophobic 
interactions and ionic bonds.  
Quaternary structure: the global shape resulting from the aggregation of multiple folded 
polypeptides which form the final functional protein.  
More recently, a fifth structural hierarchy (quinary structure) has been reported by 
Edelsteinfor interactionswithin helical arrays found for sickle cell hemoglobin fibers or tubulin 
units in microtubules.[71] 
The correct arrangement of biological macromolecules in a specific tridimensional disposition 
is highly required in order to generate their “active site”. Thus, elucidating the relationship 
between the folding pattern and the activity of biopolymers may allow the de novodesign of 
biomimetic polymers with interesting conformational and functional propensities.  
Artificially folded molecular architectures or foldamers are defined as oligomers with a strong 
tendency to fold into specific compact conformations, stabilized by non-covalent interactions 
between non-adjacent residues in solution.[3,63] In the past decades, the design and synthesis 
of a variety of foldamers and their corresponding biliduing blocks have been the interest of 
many research groups. However, producing polymers with high molecular weight that can 
mimic thoroughly the sophisticated functions and structures of bio-macromolecules is still 
limited.  
There are several important principles that govern the design of foldamers with suitable 
properties such as (i) the modification of an existing peptide by modulating either the amino 
acid side chains or the backbone itself, (ii) the insertion of constraints to elucidate the rules 
that govern the mechanisms of proteins folding[64] and (iii) the evolution of patterns to 
stabilize the secondary structure of short chains.[65,66] 
According to the nature of their single monomer unit, foldamers can be grouped into two 
major types as elucidated in Figure 2.2: “Aliphatic foldamers” that contain saturated carbon 
chains between the amide and carbonyl groups and “aromatic foldamers” that reveal 
aromatic moieties within their backbone.[119] The intact synthesis and functions of these 
unnatural polymers may provide significant applications in pharmaceutics and nanomedicine 
material sciences.  




Figure 2.2: Examples of foldamer backbones.[119] 
 
2.2 β-Peptides 
At present, the family of β-peptides is considered as most desirable mimics of natural peptides 
compared to other aliphatic foldamers. Kovacs et al. have reported the first model of 
thehelical structure of β-peptides composed of a poly(β-L-aspartic acid) in solution.[72] They 
proposed that the helical conformation of this β-polypeptide chain consists of 3.4 residues per 
turn and an axial translation of 1.58 Å. Over the next decades, structural and synthetic 
investigations of many research groups, especially the pioneering works of the Seebach and 
the Gellman group, have laid a solid foundation for a better understanding of the folding 
behavior of β-peptides in solution and in solid state.[67-70] 
β-Peptides are unnatural polymers made up solely of β-amino acids that differ from their 
natural α-amino acids counterparts by one additional methylene group either between the 
carbonyl groups and the α-carbon atoms (β3) or between the α-carbon and nitrogen atoms 
(β2) (Figure 2.3A).[73] The Cβ-substituted β-amino acids can be formed by homologation [68,74] 
or by other known synthetic routes.[75,76] The addition of one more carbon atom into the 
polyamide backbone can be translated into the introduction of one extra torsion angle 
resulting in more degrees of conformational freedom (Figure 2.3B).  




Figure 2.3: General constitution of A) designation of the substitution pattern of β-amino acid residues and B) the 
backbone torsions. 
 
It is especially interesting and might be even surprising that β-peptides are able to form 
conformations characteristically similar to those occurring in natural peptides and proteins. 
Indeed, based on the high flexibility of glycine-rich peptides, it is expected that β-peptides 
possess higher conformational flexibility due to the introduction of additional C-C bonds and 
thereby, the formation of ordered conformations is entropically disfavored. In contrast to this 
anticipated aspect, β-peptides showed a high ability to form a rich variety of regular 
conformational states. Concerning α-peptides, the formation of stable α-helical secondary 
structures required at least a chain length of 15 α-amino acids.[77] In the case of β-peptides, 
one can expect that even higher number of stretches would be required to form stable 
secondary structures due to their high number of possible conformers. However, β-peptides 
are able to show stable secondary structures even when the chain lengths contain as few as 
six amino acids.[78] As highlighted previously, β-peptides adopt a wide array of distinctive 
secondary structural motifs including helices, hairpins and parallel sheets.[79] According to the 
nature of their units, β-peptides are able to adopt different helical secondary structures, 
Artificially Folded Molecular Structures 
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among which the 14-helix, 12-helix, 10/12-helix, 10-helix and the 8-helix (Figure 2.4). The 
nomenclature of β-helical conformations varied widely in the literature. Herein, the 
nomenclature is based on the number of the atoms in the hydrogen-bonded ring.[95] 
The overall helical parameters of β-peptides differ significantlyin many aspects from the ones 
of the α-helix, such as the radius, the number of residues per turn and the overall dipole 
(Figure 2.5 and Table 2.1).  
 
 
Figure 2.4: Possible intramolecular hydrogen-bond arrangements in β-peptides.[3] 
 
2.2.1 14-Helical Secondary Structure: 
The 14-helical secondary structure is one type of the β-peptide conformations, which is 
stabilized by a hydrogen bond between an amide proton (N-H) at residue i and a main chain 
carbonyl (C=O) at residue i+2, creating a series of intercatenated 14-membered rings.[1] 
Furthermore, the extended backbone length in the case of the 14-helix changes the array of 
side chains around the helical axis giving a rise to 3 residues per turn, compared to 3.6 residues 
in the case of the α-helix. Unlike the more widely splayed arrangement found in α-helix, this 
integer phase results in side chains that are stacked almost directly atop one another in three 
linear sides with side chains aligned at 120° intervals when viewed from top of the helix axis 
(Figure 2.5). 
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Similar to α-peptides, the intramolecular hydrogen bonds in β-peptides are stabilized by the 
presence of amide bonds; however, in the case of the 14-helix the amide carbonyl and NH 
groups project toward the N- and C-terminus, respectively, which result in a net macro-dipole 
opposite to that of the α-helix.  
In terms of chirality, the 14-helix composed of L-β3-amino acids tends to be left-handed, rather 





Figure 2.5: Lateral and top views of ideal α- and β-peptide helices. Carbon atoms are shown in black, oxygens in 
red, nitrogens in blue, amide hydrogens in white and other hydrogen atoms have been omitted for clarity.[2] 
 
Gellman’s and Seebach’s groups have been especially interested in studying the essential 
interactions contributingto the stability of β-peptide secondary structures based on different 
strategies. On the one hand, Gellman’s group hasfocused on conformationally constrained 
residues that limit the degree of freedom between Cα and the Cβ bonds by introducing cyclic 
β-amino acids such as the six-membered ring trans-2-aminocyclohexane carboxylic acid 
310-helix α-helix 10/12-helix 12-helix 14-helix 
α-Peptide helices β-Peptide helices 
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(ACHC)[83-86] and the five-membered ring trans-2-aminocyclopentanecarboxylic acid 
(ACPC).[70,87-89] On the other hand, Seebach’s group haspursued the design of β-peptides based 
on sequences with minimal conformational restrictions that display more resemblance to the 
natural α-peptides.  
 
Table 2.1: Torsional angles and helical parameters of α-helix, 14-helix and 12-helix. 
Structure residue/turn rise (Å) radius (Å) pitch (Å) ϕ (°) θ (°) ψ (°) ω (°) 
α-helix[80] 3.6 1.5 2.2 5.4 -57 - -47 180 
14-helix[81] 3.0  1.6 (1.7)[90] 2.7 5 (5.2) -134.3 60 -139.9 180 
12-helix[82] 2.5 (2.7) 2.1 (2.2) 2.3 5.6 (5.9) 95.0 -94.3 103.0 -180 
 
 
Gellman and coworkers showed that the oligomer 1 (Figure 2.6) with six ACHC units strongly 
favors the 14-helical conformation in solid state as well as in solution as indicated by 
crystallographic and NMR studies.[83,84] 
 
 
Figure2.6: β-Peptide oligomers 1-3 were designed to achieve the formation of the 14-helix. 
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However, due to the high hydrophobicity of these residues, the utility of β-peptides containing 
a large proportion of ACHC in a biological context is very limited. To address this limitation and 
improve the solubility of these residues in aqueous media, one additional amino moiety has 
been inserted to the cyclic ring of ACHC resulting in the formation of DCHC (R,R,R-2,5-
diaminocyclohexanecarboxylic acid) (oligomer 2).[92] Furthermore, they have reported a 10-
residue β-peptide formed from the hydrophobic ACHC and the polar β3-Lysine rich sequence 
(oligomer 3). These amphiphilic 10-residue β-peptide tends to adopt a stable 14-helix and 
forms soluble aggregates in a tetramer-hexamer size range in a buffered solution at pH 8 as 
judged by sedimentation equilibrium data.[6] 
Likewise, several studies from Seebach and his group have shed light on the rules governing 
the stability of the 14-helix. In 1996, they reported the first helical β-peptide consisting of six 
residues, which can characteristically fold into a 14-helix as assessed by CD, NMR and X-ray 
crystal-structure analysis (oligomer 4).[93]  
 
 
Figure 2.7: β-Peptide oligomers 4-6 composed of β-amino acids that fold into a 14-helical structure. 
 
Subsequently, they synthesized a series of β-peptides derived from the oligomer 4 in order to 
explore the structural characteristics that control the stability of the 14-helix including 
oligomers 5 and 6 (Figure 2.7). In the case of oligomer 5, they added the residue β2,3-Alanine 
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(β2,3-Ala) in the central position of the sequence, whereas in the case of oligomer 6 they 
altered the stereochemistry of the β-amino acids.[67,94] 
The 14-helix is a very distinctive conformation since the residues projected from the positions 
i and i+3 are quite near to each other (4.8 Å) and nearly parallel to one another, which is similar 
to the β-sheet structure among conventional peptides (Figure 2.5). Consequently, the 
geometry of the 14-helix is considered as a key element to increase the extent of its stability 
by introducing covalent and non-covalent interactions between the side chain 
juxtapositions.[95] In 2001, Seebach demonstrated that the formation of salt-bridges within a 
water-soluble β-heptapeptidic helix by introducing two pairs of β3-homoornithine and β3-
homoglutamic acid residues having an opposite charge can enhance the stability of the 14-
helical conformation in methanol as indicated by NMR structural data and CD analysis 
(oligomer 7).[98] Independently, Cheng et al. have reported that the electrostatic interactions 
between the side chains of acyclic β-residues at position i and  position i+3 can be used to 
increase the stability of the 14-helix of a 15-mer β-oligomer 8 in water.[99] 
 
 
Figure 2.8: β-Peptide oligomers 7-9 were designed to explore the stability of the 14-helix. 
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In comparison between the oligomers 7 and 8 (Figure 2.8), Seebach’s β-peptide 7 (with 7 
residues) is shorter than Cheng’s β-peptide 8 (with 15 residues) and contains a less number of 
salt-bridges, thus it is not surprising that the latter is more stable as evidenced by CD 
spectroscopy. Additionally, it was demonstrated from both oligomers 7 and 8, that changing 
the salt concentration or pH value of the buffer can significantly decrease the overall structure 
of the 14-helix, suggesting the powerful role of electrostatic interactions in stabilizing the 14-
helix. Thereafter, Hart et al. havedemonstrated that the extent of 14-helicity in β-
undecapeptides can be increased in a different but complementary manner by replacing 
charged amino acids to minimize the overall macro-dipole of the 14-helix in water (oligomer 
9).[100] 
Another impact of side-chain pattern on the conformation preference in the case of the 14-
helix has been addressed by Ruepling and coworkers, indicating that the disulfide bridge 
between two cysteine side chains in positions i and i+3 strongly stabilize the 14-helix.[96] In the 
same way, DeGrado and coworkers have shown that stapling two 14-helices together via a 
disulfide bond showed a greater degree of 14-helicity relative to their monohelical 
counterparts by cooperatively stabilizing the secondary structure via a hydrophobic 
interaction interface between the covalent dimer (Figure 2.9).[97] 
 
 
Figure 2.9:schematic illustartion of a disulfide-crosslinked parallel β-helical bundle withapolaramino acids 
(colored spheres) that interact at the helical interface. [97] 
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2.2.2 12-Helical Secondary Structure: 
Gellman et al. have demonstrated that the cyclohexyl ACHC can stabilize the θtorsional angle 
to a value of about ± 60°, which can precisely stabilize the 14-helical conformation. However, 
using the cyclopentyl ring of ACPC instead of ACHC biases θtowardshigher values rendering a 
novel helical shape, the 12- helix, as the most appropriate helical conformer (Figure 2.10).[70] 
 
 
Figure 2.10: Top and perpendicular views of the 14-helix decamer consisting of trans-ACHC (left) and the 12-helix 
decamer consisting of trans-ACPC (right).[70] 
 
The 12-helix is stabilized by hydrogen bondings between the backbone amides at positions i 
and i+3. It consists of approximately 2.5 residues per turn and exhibites the same dipole 
moment as the α-helix, with amide protons exposed from the N-terminus of the helix (Figure 
2.5 and Table 2.1). In organic solvents, the 12-helical conformation of a β-peptide containing 
as few as six ACPC residues is very stable. However, β-peptides composed solely of these 
apolar residues are not soluble in aqueous solutions. To overcome this problem, additional 
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pyrrolidinyl amino acid trans-3-aminopyrrolidine-4-carboxylic acid (APC) was introduced to 
the β-peptides along with ACPC building blocks (oligomers 10-12).[101]  
 
 
Figure 2.11: Chemical structure of oligomers 10, 11 and 12. 
 
Using CD spectroscopy, it has been shown that a sequence containing as few as four ACP 
residues can fold into a 12-helical conformation in aqueous solution. Moreover, the 
propensity of the heterocyclic APC residues to fold into 12-helix is as high as their carbacyclic 
ACPC analogues. 
 
2.2.3 Other Conformations of β-Peptides: 
Besides the more prevalent 14-helix and 12-helix, Seebach and his group have demonstrated 
that a short β-peptide with six alternating β2- and β3-amino acids can adopt a 10/12-helical 
motif (Figure 2.4).[68] In opposite to the uniform alignment of amide bonds in the case of the 
14- and the 12- helical axis (Figure 2.5), the 10/12 helix is featured by an intertwined network 
of 10- and 12- membered hydrogen-bonded rings. Additionally, this helix shows two types of 
amide bond orientations, resulting in a nullified macro-dipole moment. In addition to the well-
defined helices described above, other helical structures have also been detected in β-
peptides, including 10-, 8-, 16-, 18- and 20-helix.  
More recently, Fleet et al.have investigated a β-hexapeptide, in which the peptide backbone 
was constrained by monomers with four-membered oxetane rings (Figure 2.12A). The two-
dimensional NMR studies with molecular mechanics conformational analysis reveal that this 
β-hexapeptide tends to fold into a well-known left-handed helical conformation stabilized by 
10-membered hydrogen-bonded rings.[102] 




Figure 2.12: Molecular structure of A) oxetane ring β-amino acids and B) 1 (aminomethyl)cyclopropanecarboxylic 
acid. 
 
Additionally, the 8-helical conformation was determined by Abele et al. for short oligomers 
containing a chain of the achiral monomer1-(aminomethyl) cyclopropanecarboxylic acid as 
detailed by X-ray crystal structural data (Figure 2.12B).[112] The obtained results indicate that 
longer oligomers of this type might adopt regular eight-membered ring hydrogen bonds that 
would characterized by approximately two residues per turn. 
Apart from the known helical conformations, β-peptide foldamers are also able to adopt 
sheet-like secondary structures. For example, a β-polypeptide composed of solely β-alanine 
residues can be crystallized as an extended sheet-like structure[104]; however, it showed a 
disordered structure in solution.[105]  
As presented in Figure 2.13, sheet conformations of β-peptides can be mainly devided into 
two types, in which the residue adopts either an anti Cα-Cβ or a gauche Cα-Cβ torsion angle. 
Similar to β-sheets formed by α-peptides, β-peptide sheet formed by amino acids with gauche 
Cα-Cβtorsion angles would lack a net dipole since the backbone carbonyls alternate in direction 
along each strand. However, this is not the case for β-peptide sheets formed by anti Cα-Cβ 
torsion angles because all the carbonyls in the backbone are oriented in nearly the same 
direction, hence, giving a net dipole for the resulting sheet.[106] 
 




Figure 2.13: The two types of antiparallel β-peptide sheet structures in which the residues adopt either an anti 
Cα-Cβ torsion angle (left) or gauche Cα-Cβ torsion angle (right). 
 
2.3 Biological Functions of β-Peptides 
Due to their controllable structural motifs, β-peptides are idealbiomimetic polymer scaffolds 
that allow the design of sequences with promising activities and highly interesting in diverse 
biomedical applications. Especially the 14-helix provides an appropriate patterned backbone 
that has been widely used by many research groups as a target to arrange amphiphilic 
sequences. In fact, Seebach and co-workers have shown that there is a correlation between 
the ability of β-peptides to fold into stable 14-helical foldamers in methanol and their 
inhibitory effecton sterol and lipid absorption.[107] They introduced first-generation models of 
short amphiphilic 14-helices capable of mimicking the biological activity of natural peptides 
by inhibiting cholesterol and fat uptake in human colonic carcinoma cells. Despite having less 
potent inhibitory effect compared to their α-peptide analogous, these bioactive β-peptides 
are consisted of much less number of residues and targeted to a specific receptor-mediated 
process. Besides, it has been demonstrated that β-peptides are stable towards proteolytic 
degradation in vitro as well as in vivo,[93,108,109] and they have the ability to penetrate cell 
membranes to be localized within the cell nuclei.[110-113] Thereby, β-peptides should be 
considered as promising new-generation therapeutic models in the medicinal viewpoint.  
Understanding the effect of hydrophobic/hydrophilic balance, chain length and helix-forming 
potential is highly important to optimize the selectivity and the affinity of α-helical 
antibacterial peptides.[114] In a similar way, the design of β-peptides with graded amphiphilicity 
and helix stability would be interesting in order to allow optimization of their affinity and 
selectivity. Taking the advantageous geometry of the 14-helix into account, DeGrado et al. 
have described the design of positively charged β-peptides that have the ability to mimic the 
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Figure 2.14: A) The top[115] and B) the side[116] views of an amphiphilic β-peptide containing β3-Val, β3-Leu and β3-
Lys. Carbon atoms are shown in green, nitrogens in blue, and oxygens in red. 
 
The biological activities of these β-peptides were tested using human erythrocytes as models 
for mammalian cellsandEscherichia coli as modelsfor bacteria. The data have shown that these 
compounds were capable of suppressing bacterial cell growth by disrupting the structural 
integrity of their phospholipid membranes. Although these β-peptidefirst-generation models 
were reasonably active with IC50 values in the minimal micromolar range, they generally 
showed poor discrimination between bacteria versus mammalian cells. In further studies, they 
have optimized the hydrophobicity of these β-peptides by changing the hydrophobic β3-Val 
and β3-Leu by the less hydrophobic β3-Ala, which resulted in significantly improved 
selectivities and potencies.[116] 
In the same way, the design of antimicrobial β-peptides that can form 12-helical 
conformations rather than 14-helices was possible by using the oligomer 13 (Figure 2.15), 
which contains both, positively charged APC and hydrophobic ACPC residues.[117] Theseβ-
peptides are highly potent and very specific towards bacteria, exhibiting an excellent activity 
against four bacterial species including two pathogens,which are resistant to common 
antibiotics. 
A B 





Figure 2.15: β-Peptide oligomers 13 and 14 were designed to investigate the biological acitivity of the 12-helix in 
the case of the oligomer 13 and the 10/12 helix in the case of the oligomer 14. 
 
Regarding the 10/12 helix, the bioavailability of β-peptides formed by alternating β2- and β3-
amino acids is expected to be notably enhanced due to the the lack of a net macro-dipole 
moment. Thus, Seebach and his group have revealed that the β2/β3-nonapeptide (oligomer 
14) can adopt an amphiphilic right-handed 10/12/10-helix, showing a remarkable antibacterial 
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3 Design and Synthesis of β-Peptides 
3.1 Design ofβ-Peptides 
Transmembrane (TM) proteins are abundantly found in nature and account for about 20-30% 
of the open reading frames of the exemplary genomes.[121,122] However, the three-dimensional 
structure of membrane proteins is still poorly understood. It has long been recognized that 
helix-helix interactions play a key role in stabilizing membrane proteins.[45] In this regard, 
several studies pointed out the importance of tight packing and specific residues to better 
investigate helical association of membrane proteins.[123,124] 
Recently, β-peptides are of major interest in the field of self-organizing systems due to their 
tendency to form side-chain-controllable compact conformations and by virtue of the wide 
range of their potential applications in themedicinaldomain.[68,125-128] Using the special pattern 
of β-peptides, the major goal of this study is to better understand the function and the 
mobility of transmembrane proteins by electrostatically stabilizing their tertiary structures 
using non-covalent interactions. Generally, the stability of a protein tertiary structure depends 
strongly on the number, size and arrangement of its residues. Therefore, the judicious choice 
of amino acids allows the formation of helices with well-defined conformations that can be 
used as templates for directing the spatial arrangement of peptides.  
The unique side chain alignment of the 14-helical secondary structure was exploited by several 
researchers to orient the formation of helical bundles (see section 2.2). This helix is obtained 
by using β-amino acids having lateral substituents in β-position or by using the cyclic ACHC 
amino acid.[127] On the other side, the β-peptide 12-helix merits a particular attention as it 
bears some similarity to the natural α-helix commonly formed by conventional peptides.[11] 
All these convenient characteristics suggest that both 14- and 12-helices might be reasonable 
platforms for molecular recognition. Hence, the choice of the sequences in this study is based 
on the formation of stable 14- and 12-helices as they can offer rigid and well-known patterns. 
For this purpose, the sequences P0 and P5 were designed to achieve the formation of 14- and 
12-helix, respectively (Figure 3.1). Subsequently, these two sequences were used as initial 
references to design other sequences bearing residues that can create an additional force to 
drive helix-helix assembly in a regular way. Taking into account that these β-peptides will be 
used as TM model proteins, the transmembrane-buried part of these sequences was mostly 
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composed of hydrophobic amino acids. However, many TM proteins in nature might contain 
polar amino acids that contribute to helix-helix interactions, co-factor binding, etc.[120] 
 
 
Figure 3.1: Molecular structure of theβ-peptides P0 and P5. 
 
3.1.1 Structural Design of the 14-Helix 
The oligomer P0 was basically designed to promote the formation of 14-helical backbone. This 
structure would display a well-explained scaffold that can be used to incorporate recognition 
units, which in turn would instigate the helices association driven by hydrogen bonding. As 
illustrated in Figure 3.1, the membrane-spanning region of P0 possesses a long chain 
containing 19 residues of hydrophobic β3-valines (β3-Val) followed by the presence of two β3-
tryptophans (β3-Trp) and two β3-lysines (β3-Lys) at each end of the sequence.  
The choice of β3-Val was guided by the notion that these residues can efficiently enhance the 
extent of β-peptides to fold into a stable 14-helical motif. Indeed, studies from several 
research groups demonstrate that the use of these aliphatic side chains induces the 14-helicity 
in different aqueous solutions.[100,115,131,132] Furthermore, the length of the hydrophobic 
stretch of β-peptide P0 was adjusted to match the apolar region of the lipid model system 
used in this study, which composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 
POPC (Figure 3.2) . 




Figure 3.2: Chemical structure of POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine). 
 
The interfacial region of P0 was further enriched by the addition of two aromatic side chains 
β3-Trp. This was inspired from the structure of Gramicidin A (gA), a small Trp-flanked ion 
channel that has been broadly explored in membrane environment.[23,52,133,134] Generally, the 
indole side chain of Trp  appears to localize in the interface of the membrane.[137] On the one 
hand, it consists of a hydrophobic aromatic ring that might be preferentially positioned in the 
apolar region of the lipid bilayer. The amide group linked to the aromatic ring of Trp confers 
polarity and considerable dipole moment to the overall side chain and thereby, it is expected 
to be localized in the more polar environment at the polar-apolar region.[34] These versatile 
molecular properties of Trp render it as an ideal amphiphilic residue to anchor and stabilize 
the peptide in the membrane-water interface since its indole N-H-moiety exhibit a great 
electrostatic potential for cations-π interactions and capable of hydrogen bond donation.[135] 
Since most biological events occur in aqueous media, it was highly desirable to add polar 
amino acids in order to increase the solubility of P0 in aqueous solutions. Thus, two molecules 
of β3-Lys were attached to flank the hydrophobic stretch of P0 on both N- and C-terminus. This 
polar amino acid has a relatively long and flexible aliphatic side chain that is ended with a 
positively charged amine. The flanking β3-Lys side chains are expected to extend into the polar 
interface around the lipid phosphate group or more precisely towards the water-membrane 
interface.[34,136] 
In summary, the particular choice of the molecular composition of P0 implies that this 
foldamer has the ability to show a 14-helical secondary structure, which offers a well-designed 
scaffold by containing three spatial streaks stacking almost directly atop one another (Figure 
3.3 right).  
 




Figure 3.3: Left) Schematic illustration of P0 and right)[138] top view of the 14-helix. 
 
The advantageous structure of 14-conformations is expected to form an appropriate helical-
wheel representation to specifically introduce residues capable of creating covalent and non-
covalent interactions that can successively mediate the association of the transmembrane 
helices.  
Interhelical hydrogen bonds within TM proteins are thought to play a dynamic role by 
improving the stability and the specificity of TM helices association.[59] However, structural 
contributions of polar residues in the membrane are less well understood. Interestingly, 
studies from DeGrado and Engelman have demonstrated that the insertion of residues with 
polar side chain such as Asn, Gln, Asp or Glu can strongly promote helix-helix association of α-
helices in both micelles and biological membranes via side chain-side chain hydrogen 
bonding.[49,50,59] Based on the same concept, we have specifically placed the polarβ3-
glutamines (β3-Gln) within the foldamer P0 to investigate whether the interhelical hydrogen 
bond created by the side chains of these residues can drive organized self-assembly of the 14-
helices.  For this reason, the buried β3-Val molecules across one linear side of P0 were 
specifically substituted at positions i and i+3 by one, two and three β3-glutamines (β3-Gln) 
resulting in the formation of the β-sequences P1, P2 and P3,respectively (Figure 3.4). 
 
 




Figure3.4: Molecular structure of the helices P1 (with one β3-Gln), P2 (with two β3-Gln),P3(with threeβ3-Gln). 
 
The polar Gln residue is among the amino acids containing a side chain that can 
characteristically act as both hydrogen bond donor and acceptor, resulting inhomo-
aggregation of the helices (Figure 3.5). 
 
 
Figure 3.5: Hydrogen bonding resulted from interactions between the polar side chains of the β3-Gln. 
 
Similarly, it has been also demonstrated that including polar asparagines (Asn) within the 
helices can result in their self-assembly due to hydrogen bond interactions. [49,50,59] However, 
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the side chain of Gln is more flexible than Asn by having one additional CH2-moiety rendering 
the former more suitable choice in this study. 
Additionally, the inclusion of β3-Gln was performed in such a way to fulfill a symmetrical 
distribution of these residues within the 14-helices with the aim to facilitate hydrogen bonding 
interactions in either parallel or anti-parallel mode of oligomerization (Figure 3.6). 
 
 
Figure 3.6: Schematic illustration of the helicesP1 (with one β3-Gln), P2 (with two β3-Gln) andP3 (with three β3-
Gln). 
 
The concept of high organization of the 14-helical backbone can be further extended by 
positioning recognition units not only in one side of the14-helix but also in two sides. To this 
end, two sides of the sequence P0 were subsequently functionalized by substituting two 
molecules of the buried β3-Val in each side with the polar residues β3-Gln, generating the 
sequence P4 (Figure 3.7). 
The architecture of the helix P4 can easily facilitate the formation of hydrogen bond between 
β3-Glnside chains across turns of the helix, which might be featured by creating a system with 
higher order aggregates. Nevertheless, the exact number of the subunits existing in the same 
oligomer strongly depends on the distribution of β3-Gln residues, the overall geometry of the 
helix and the parallel anti-parallel orientation mode of the helices.  
 
 




Figure 3.7: Top) Molecular structure of P4 containing four β3-Gln and bottom) Schematic illustration of the helix 
P4. 
 
3.1.2 Structural Design of the 12-Helix 
In analogy toP0, the β-peptide P5 was designed to fold into a12-helical conformation. It is well 
known that the structural conformation of the 12-helix differs widely from that of the 14-helix 
in many aspects (see section 2.2). For instance, in the case of the 12-helical secondary 
structure, the length of the helix is greater than that of the 14-helix and therefore, it was 
required to decrease the number of the amino acids forming the hydrophobic stretch of the 
helix to match the apolar region of the lipid bilayer POPC. Thus, 15 hydrophobic β3-leucines 
(β3-Leu) amino acids were sufficient to form the hydrophobic core of the β-peptide P5.  
In contrast to β3-Val, it has been observed that the use of β3-Leu tends to decrease the stability 
of the 14-helical secondary structure[2] and, instead increases the tendency of the β-peptides 
to fold into 12-helical conformations.[132,139] Keeping the same concept as in the case of P0, 
β3-Trp and β3-Lys were positioned to flank the hydrophobic stretch of P5 (Figure 3.8 left).  
 




Figure 3.8: Left) Schematic illustration of P5 and right) projection along the 12-helical axis assuming 2.5 residues 
per turn. 
 
The conformational properties of the 12-helix restrict the placement of functional groups at 
specific sites along the helix, which render the inclusion of β3-Gln residues more challenging 
since the three-dimensional arrangement of this helix is more splayed in the space compared 
to the 14-helix by having approximately 2.5 residues per turn (Figure 3.8B).[130] For this reason, 
one, two and three β3-Leu were substituted within the helix P5 at positions i and i+5 (every 








Figure 3.9: Molecular structure of the helices P6 (with one β3-Gln), P7(with two β3-Gln), P8(with three β3-Gln). 
 
Undesirably, the architecture of the 12-helical scaffold prevents the symmetrical distribution 
of β3-Gln amino acids within the helix, which means that hydrogen bond interactions within 
the β3-Gln side chains along the 12-helices might be limitedby the parallel orientation of the 
sequences (Figure 3.10). 
 
 
Figure 3.10: Schematic illustration of the helices P6 (with one β3-Gln), P7 (with two β3-Gln) and P8 (with three 
β3-Gln). 
 
3.2 Synthesis ofβ-Peptides 
3.2.1 Synthesis of D-β3-Amino Acids 
D-β3-Amino acids were readily prepared in very good yields from their D-α-amino acid 
counterparts through Arndt-Eistert homologation.[78,138,150,151] This method leaves the stereo-
center at the α-carbon intact and precisely inserts a CH2-group into the amino acid backbone. 
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Thus, the resultingD-β3-amino acids were enantiomerically pure and no racemization has been 
observed. As a first step, the D-α-amino acids were reacted with isobutyl chloroformate to 
obtain the activated esters. Then, the diazoketones were afforded by the subsequent 
nucleophilic attack of diazomethane (added as an ethereal solution) at the activated carbonyl 
centers as presented in Scheme 3.1. Finally, Wolff rearrangement was catalyzed by adding 
silver benzoate to the diazoketones, giving rise to the finale D-β3-amino acids after releasing 
N2-group.  
The D-β3-Lys, D-β3-Trp and D-β3-Gln were orthogonally protected with different protecting 
groups to avert undesirable side reactions. 
 
 
Scheme 3.1: Synthetic approach for the preparation ofD-β3-amino acids from their D-α-amino acid counterparts 
usingArndt-Eistert reaction. 
 
3.2.2 Synthesis of β-Peptides 
The β-peptides have been synthesized manually using a microwave-assisted Fmoc-solid-phase 
peptide synthesis (SPPS).[2,89,132,142] Usually, both the synthesis and purification of β-peptides 
that contain approximately more than 10 residues in length can be difficult, especially in the 
case of very hydrophobic β-sequences. Nevertheless, the method adopted in this study 
allowed the preparation and the purification of the target foldamers by modifying some 
conditions during the β-peptides synthesis. Thus, two different methods have been adopted, 
first for β-peptides containing a large amount of β3-Val and second for β-peptides containing 
a large amount of β3-Leu. A schematic representation for the stepwise synthesis of β-peptides 
containing β3-Val using MBHA rink amide resin (loading capacity of 0.57 mmol/g) is shown in 
Figure3.11.  




Figure 3.11: Stepwise Fmoc-based solid-phase peptide synthesis (SPPS) for β-peptides on MBHA rink amide 
resin. 
 
The synthesis of these sequences began with loading the resin with D-β3-Fmoc-Lys(Boc)-OH 
followed by removing the Fmoc-protecting group under basic conditions using 20% piperidine 
in NMP. Subsequently, the next coupling was performed twice (20 min in each) after pre-
activating the ester of the desired D-β3-amino acid with a mixture of HATU/HOAt/DIPEA at 
50 °C. The procedure of deprotection and coupling was successively repeated until the desired 
chain length was reached. Finally, the β-peptide was cleaved from the resin under acidic 
conditions using a cocktail of TFA/H2O/TIS (95%/2.5%/2.5%).  
β-Peptides containing a large amount of D-β3-Leu are more hydrophobic and prone to 
aggregateeasily, leading to incomplete reactions during the synthesis especially after the fifth 
or the sixth residue.[143,144] Thus, different conditions have been pursued in this study to 
overcome the problem of aggregation due to the high hydrophobicity of the sequences 
Design and Synthesis of β-Peptides 
 
39 
containing D-β3-Leu: (i) the rink amide MBHA resin was replaced by the less apolar NovaPEG 
rink amide LL resin (loading capacity of 0.18 mmol/g), which has been used in many cases for 
the synthesis of very hydrophobic sequences,[148,149] (ii) after coupling the sixth residue, the 
use of DBU (1,8-Diazabicyclo[5.4.0]undec-7-ene) along with  piperidine was essential to 
efficiently remove the Fmoc-protecting group. [142,144] Therefore, a mixture of 10% DBU and 
10% piperidine in NMP was used as a deprotecting solution, (iii) coupling at higher 
temperature can interrupt interactions causing the aggregation in many cases for very 
hydrophobic peptides;[145,146] however, the very high temperature might lead to undesirable 
side reactions.[147] Herein, the temperatures during the peptide elongation was elevated up to 
75 °C, (iv) after the sixth amino acid, the coupling time was elongated to 30 min, instead of 20 
min, and (v) during the synthesis of all the β-peptides (including β-peptide containing D-β3-
Val), NMP was selected as a solvent for each step to dissolve the D-β3-amino acid because 
most peptide building blocks and reagents are well soluble in NMP.[140,141]Using the previous 
conditions, the synthesis ofβ-peptides containing a large number of hydrophobic β3-
Leuresidues was possible. 
In order to measure FRET, the donor NBD (4-chloro-7-nitrobenzo-2-oxa-1,3-diazol) and the 
acceptor TAMRA (5(6)-carboxytetramethylrhodamine) were selected as pair of fluorophores 
and attached to the last β3-Lys at the N-terminus inall synthesized β-peptides (Figure3.12). For 
this reason, a third β3-Lys was added to the N-terminus of the β-peptides in order to maintain 
the relative solubility of these sequences in aqueous media.  
Labeling β-peptides was accomplished on resin using DIPEA and PyBOP (in the case of the 
acceptor TAMRA) in NMP, over night and at room temperature.  
 
 
Figure 3.12: Chemical structure of NBD (right) and TAMRA (left). 
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Finally, the obtained β-oligomers were purified with HPLC using a C18 reversed-phase 
columnand characterized by mass spectrometry. Table 3.1 represents the sequences of all 
synthesized transmembraneβ-peptides as well as their fluorescent labeled-
analoguespreparedfor FRET measurements.  
 






































































4 Structural Characterization 
4.1 CD Spectroscopy 
4.1.1 Theoretical Basis 
Circular dichroism (CD) spectroscopy has been increasingly recognized as a valuable technique 
to reveal the secondary structures of proteins and peptides in different and predictable ways. 
For CD spectroscopy, the idea of circularly polarized light is considered as the most important 
physical/optical concept. Thus, the polarized beam of light is composed of right- (R) and left- 
(L) handed circularly polarized components, in which the difference in their absorption can be 
measured and quantified using the equation:A = AL - AR (Figure 4.1).[152,153] The theoretical 
background of CD spectroscopy and its application to study the types of molecules has been 
broadly covered in the literature.[152,155-157] 
 
 
Figure 4.1: Left (L) and right (R) circularly polarized components of plane polarized radiation: (I) Linear polarized 
light can be viewed as a superposition of opposite circular polarized light of equal amplitude and phase; (II) 






The CD spectrum in the far UV region (240-180 nm), corresponding to the absorption of the 
peptide bond (amide chromophore), can be examined to give information about regular 
conformational characteristics, such as α-helix and β-sheet. On the other hand, the CD 
spectrum in the near UV region (320-260 nm), which is correlated to the environments of 
aromatic side chains candisplay the content of proteins tertiary structure.[152]Nevertheless, 
several amino acid side chains (notably Tyr, Trp, Phe, His, and Met) can absorb light strongly 
in the far UV region (below 250 nm).[154] 
 
4.1.2 Secondary Structure of β-Peptides in Solution and within the Membrane 
CD spectroscopy has been widely utilized to analyze various types of β-peptide secondary 
structures in different environments.[78,95,142] In this study, the helicity of the synthesized β-
peptides was analyzed using the same technique outside and inside artificial lipid membranes. 
It has been shown that β-peptides adopting left-handed 14-helixdisplay a maximum near 195 
nm and a minimum near 215 nm and vice versa for right-handed 14-helix. On the other hand, 
the experimental CD spectra of a 12-helical pattern have been diagnosed by showing a 
maximum near 200-205 nm and two minima near 220 nm and 190 nm. However, the 
magnitude of the ellipticities (θ) can be varied based on the helix content as well as the 
surrounding milieu.[95,132]As it is the case for α-helices, the intensity of the CD spectrum for β-
peptides appears to be length-dependent by showing more intense ellipticity as the helix is 
lengthened.[115] 
As it was previously described, the backbones of β-peptides P0 and P5were consistently pre-
organized to show 14- and 12-helical conformations, respectively (see section 3.1). As a first 
step, the secondary structures of these two β-peptides was investigated in 2,2,2-
trifluoroethanol (TFE). The main concern over using TFE in this study is its ability to induce 
helical structure to the native conformationof peptides and proteins.[158,159] The dielectric 
constant of TFE is about one third compared to that of water and more closely approximates 
to that of the interior of proteins, which would favorably strengthen the intramolecular 
hydrogen bonds and therefore stabilize the peptide secondary structure.[160] 
The results depicted in Figure 4.2 represent the CD spectra obtained from measuring the 
helicity of the sequences P0 and P5 in TFE at different temperatures and a concentration of 




maximum at 210 nm and a zero crossing at ca. 202 nm. As it was expected, these bands 
characteristically display thatP0 tends to fold into a right-handed 14-helix. Basically, the right-
handed configuration was obtained due to the presence of D-β3-amino acids derived from α-
D-residues (β-peptides comprised of L-β3-residues derived from α-L-residuesdisplay opposite 
CD extrema). 
 


























































Figure 4.2: CD-spectra of β-peptides P0 (top) and P5 (bottom) in TFE at different temperatures and concentration 




In contrast, P5 exhibits a different CD spectrum from that of P0 by showing three bands, a 
maximum at 202 nm and two minima at 219 nm and 191 nm (Figure 4.2 bottom). These values 
are more likely a signature for a left-handed 12-helix.  
In conclusion, the dramatic variation between the CD spectra of P0and P5in TFE denotes that 
β3-Val and β3-Leu have very distinct secondary structuralpredilections, which is consistent 
with the view that β3-building blocks are quite malleable.[132,139] 
Additionally, the stability of both P0 and P5 patterns was further supported by recording CD 
spectra at different temperatures, showing that the structural characteristics of these helices 
were conserved even at high temperatures up to 60 °C (Figure 4.2).  
In order to analyze the effect of introducing recognition units on the secondary structures, 
analogical CD spectroscopy experiments have been performed for all other β-peptides 
(bearing one or more β3-Gln) using the same conditions. The results from measuring CD 
spectroscopy of P1, P2, P3 and P4 (β-peptides containing β3-Val) are depicted in Figure 4.3 
(top). It is clearly shown that these helices preferably maintain a neat 14-helical conformation 
by revealing similar bands compared to P0 (Table 4.1). 
Besides, Figure 4.3 (bottom) displays the helicity of P6, P7 and P8 (β-peptides containing β3-
Leu). Similarly, the propensity of these helices to fold into a 12-helical secondary structure 
seems to be retained because of exhibiting identical bands as P5 (Table 4.2).  
 




































































Figure 4.3: CD spectra of β-peptides P0, P1, P2, P3 and P4 (top) and P5, P6, P7 and P8(bottom) in TFE at 20°C and 
concentration of 30 μM. 
 
Furthermore, the β-helical conformations of all β-peptides appeared to be stable as well at 
high temperatures up to 60 °C (Figure 1.S in the “Appendix”).  
 
Table 4.1: Maximum and minimum wavelengths for P0-P4 showing a right-handed 14-helix in TFE and POPC at 
room temperature. 
 
The results from both 14- and 12-helices show a slight shift in the wavelength values from 
those existing in the literature, which is due to the different dielectric constant of the 
surrounding milieu.[166] 
 P0 P1 P2 P3 P4 
Medium TFE POPC TFE POPC TFE POPC TFE POPC TFE POPC 
λmax (nm) 210 208.5 210.5 208.5 210 208 210.5 208 210.5 208.5 
λmin (nm) 193 192 192.5 192 192 190.5 192 190.5 192 190.5 




Interestingly, all these results unambiguously confirm that varying side chains within the β-
peptides can be tolerated in the context of reasonably preserving rigid helical conformations.  
 
Table 4.2: Maximum and minimum wavelengths for P5-P8 showing a left-handed 12-helix in TFE and POPC at 
room temperature. 
 P5 P6 P7 P8 
Medium TFE POPC TFE POPC TFE POPC TFE POPC 
λmax (nm) 202 204.5 202.5 205 202.5 204.5 202 205 
λmin1 (nm) 219 223 219.5 217.5 218.5 219.5 219 218 
λmin2 (nm) 191 196.5 191 196.5 191 198 191 196.5 
Conformation Left-handed 12-helix 
 
 
Several investigations from various research groups have indicated that the spectral 
properties of proteins can be influenced by the presence of aromatic side chains such as Trp 
and Tyr (tyrosine)even when they are present at the frayed ends of the helix.[161,162,163] 
Generally, this influence can be detected in the CD spectra as an additional CD band in the 
225-250 nm region. Indeed, the CD spectra of all the β-peptides in this study show a clear band 
near 225 nm since all the sequences contain four β3-Trp residues (see section 3.1).  
From CD spectroscopy it has been confirmed that the β-peptides containing β3-Val fold into a 
14-helix and thereby, their hydrophobic stretch can be assessed to be 31.6 Å, assuming an 
ideal 14-helical conformation with three residues per turn and a pitch of 5.0 Å. In a similar 
vein, the length of the hydrophobic region of β-peptidesfolding into a 12-helix can be 
estimated to be 33.6 Å, assuming an ideal 12-helical conformation with 2.5 residues per turn 
and a pitch of 5.6 Å. It is worth mentioning that the length of the hydrophobic stretch in both 
cases surpasses the hydrocarbon region of the artificial membrane POPC used in this study, 
which is 2DC= 29.2 Å at 20 °C.[164] As a result of this phenomenon, which is known as positive 
hydrophobic mismatch, peptides as well as lipids can adopt different responses such as a 




the secondary structure for all β-peptides embedded within LUVs POPC was assessedby CD 
spectroscopy using 5:100 as peptide-to-lipid (P:L) ratio (Figure 4.4).  
 


































































Figure 4.4: CD-spectra of β-peptides P0, P1, P2, P3 and P4 (top) and P6, P7 and P8(bottom) within POPC LUVs 






The strong resemblance between the spectra of the β-peptides in TFE and within the lipid 
bilayer implies that the conformational preference of all the β-peptides was preserved, which 
greatly demonstrates the extreme stability of these sequences in various environments 
(Figure 4.4, Table 4.1 and 4.2).  
 
4.2 Fluorescence Spectroscopy 
4.2.1 Insertion of β-Peptides within the Membrane 
Numerous studies have been conducted concerning the multiple role of Trp fluorescence to 
derive inferences with respect to changes in structural characteristics of proteins as well as 
their physical and dynamical properties.[167-170] It is known that Trp residues are sensitive to 
subtle changes in their local environments, which can be clearly observed in the change of 
their fluorescence wavelength (λmax), ranging from about 308 nm to 355 nm.[167] This 
distinctive property has been used to classify the position of Trp residues according to their 
surrounding in three discrete categories.[171,172] One of these categories includes Trp 
molecules inside the protein in a low-polar environment with a wavelength maximum λmax less 
than 330 nm. The second category consists of the complete exposure of Trp residues to water 
with a wavelength maximum λmax at ca. 350 nm. The last category reflects the presence of Trp 
residues in the polar-apolar region near the membrane-water interface with a wavelength 
maximum λmax more than 330 nm. Basically, the change in Trp fluorescence wavelength is due 
to the difference between the dielectric constant imposed by the protein and the surrounding 
milieu, which strongly suggests that the orientation of Trp residues is highly correlated with 
the electric field direction.[167,168] 
Since all the synthesized β-peptides in this study contain β3-Trp, we used the fluorescence 
emission of these residues to gather an overview of β-peptides positioning within the 
membrane. The results shown in Figure 4.5 display an initial study about the β3-Trp 
fluorescence of the β-sequences P0 and P5 within the lipid bilayer composed of POPC using 
1:600 ratio as well as in TFE at concentration of 30 μM.  
As shown in Figure 4.5 (top), the fluorescence emission maximum (λmax) of P0 in TFE was 
detected at 348 nm, indicating the complete exposure of these residues to the polar 




the fluorescence emission maximum of β3-Trp was blue-shifted to be 342 nm, which reflects 
that theseresidues exist in a more hydrophobic environment in the lipid bilayer. 
Likewise, the fluorescence emission (λmax) of P5 in TFE shows a maximum at 347 nm (Figure 
4.5 bottom), meaning that Trp molecules are in a polar environment. Besides, the 
fluorescence maximum of β3-Trp residues was blue-shifted to 341 nm when P5 was integrated 
within the lipid bilayer, reporting that these residues are partially buried in the membrane 
interior. 
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Figure 4.5: The β3-Trp fluorescence spectra of P0 (top) and P5(bottom) within the lipid bilayer POPC LUVs using 




In a similar way, Trp fluorescence measurements were performed for all other β-peptides 
either in TFE or in LUVs POPC (Figure 3.S in the “Appendix”). The results showed that the 
maximumof β3-Trp emission was blue-shifted in all cases after insertion of these sequences 
into the lipid bilayer, table 4.3 regroups all the obtained data. 
 
Table 4.3: Fluorescence emission maxima of β3-Trp of the14-helices (top) and the 12-helices (bottom) β-peptides 
determined in both TFE (concentration of 30 μM) and within POPC vesicles (1:600 as peptide/lipid ratio) at room 
temperature. 
14-Helix P0 P1 P2 P3 P4 
Medium TFE POPC TFE POPC TFE POPC TFE POPC TFE POPC 
λmax (nm) 348 342 349 339 349 339 349 339 347 340 
 
 
12-Helix P5 P6 P7 P8 
Medium TFE POPC TFE POPC TFE POPC TFE POPC 
λmax (nm) 347 341 347 339 349 342 349 340 
 
Generally, the blue shift in the emission maximum of the Trp molecules in all the cases 
confirms that the environment around the Trp, after inserting the β-peptides into the lipid 
bilayer, is more hydrophobic and that all the β3-Trp amino acids are localized near the water-
membrane interface. Thus, these results suggest the transmembrane orientation of all the 









Figure 4.6: Schematic illustration of the β-sequences P0 and P5 positioning within the lipid bilayer composed of 
POPC. 
 
4.2.2 Topological Insertion of β-Peptides into the Lipid Bilayer 
Chemically modifying NBD-labeled lipids in both artificial and biological membranes by 
quenching the highly fluorescent NBD-probes using dithionite ions has been widely used to 
measure transverse-membrane asymmetry in vesicles and phospholipids translocase 
activity.[174,183] In a similar way, membrane-impermeable dithionite ions can chemically reduce 
the NBD fluorophores attached to the N-terminus of peptides and thereby, selectively quench 
the fluorescent NBD-labeled analogues. This approach allows for precisely determining the 
preferable topological insertion of the peptides into the membrane and also the location of 
the N-terminus.[177-179] 
In aqueous media, the dithionite ions (S2O42-) exist in an equilibrium with the radical anions 
SO2-.[180,181] These radicals are unable to penetrate the hydrophobic lipid bilayer and instead 
stay outside the vesicle, which causes a reduction of the electron-withdrawing nitro-group of 
the outer NBD molecules to non-fluorescent electron-donating amino-group by a single-
electron transfer pathway(Figure 4.7). Accordingly, this procedure leads to the complete 
abolishment of NBD fluorescence and the formation of new non-fluorescent molecules 
(ABD).[174] 
This method has also been used to chemically modify the amino acid side chain of nitro-






Figure4.7: Reduction of 7-nitro2,1,3-benzoxadiazol-4-yI-labelled β-peptide (R-NBD) to 7-amin2,1,3-
benzoxadiazol-4-yl- labelled β-peptide (R-ABD) with the membrane-impermeable dithionite ions. 
 
Based on that concept, we probed a more suitable mode of insertion preferred by the β-
peptides into the membrane by treating the outer leaflet of POPC liposomes containing 
fluorescently NBD-labeled probes with a freshly prepared sodium dithionite solution (Figure 
4.8).  
 
















































Figure 4.8: External addition of sodium dithionite solution to POPC LUVs containing 0.16 mol% fluorescent NBD-
labeled P0D(top)and P5D (bottom).  Fluorescence signal wavelength of NBD fluorophores was monitored at 533 
nm for excitation wavelength at 450 nm. 
 
The data depicted in Figure 4.8 show that the external addition of S2O42- to LUVs containing 
0.16 mol% of either fluorescent P0D or P5D causes a dramatic decrease in the intensity of NBD 
fluorescence by almost 64 % and 77 %, respectively, thus, indicating that the N-termini of 
about 64 % of P0D and 77 % of P5Dare situatedin the outer-leafleted of the vesicles. 
Consequently, the emission of theNBD fluorescence of about 36 % of P0D and about 23 % of 
P5D remain intact, indicating that the N-termini of 36 % of P0D and 23 % of P5D are located in 
the inner-leafleted of the vesicles.  
These findings strongly demonstrate that the β-peptides are translocated across the lipid 
bilayer and form transmembrane helices with either an N-terminus inside or outside the lipid 
bilayer (see Figure 4.S in the “Appendix”). 
In some cases, a continuous decrease in the NBD-fluorescence might be subsequently 
observed, suggesting that the dithionite ions are tardily crossing the membrane. However, the 
permeability of dithionite and SO2- radicals can alter substantially with membrane lipid 






4.3 Förster Resonance Energy Transfer Experiments 
4.3.1 Theoretical Basis 
In many biological research areas, the major interest is to precisely realise the location and 
the nature of interactions between particular molecular species. However, the usage of 
instruments with limited resolutions can often hamper the investigations to explore these 
phenomena. Fluorescence resonance energy transfer (more commonly referred to the 
acronym FRET) is a valuable technique that can permit the determination of intramolecular 
and intermolecular distances in the range of 10-100 Å, which is a sufficient distance for 
molecular interactions to take place.[184-186] FRET is a distance-dependent physical process, by 
which a donor chromophore in an excited electronic state transfers its excitation energy to a 
nearby acceptor fluorophore in a non-radiative way through long-range dipole-dipole 
coupling.[184,187-190] 
 
                                                         D* + A                 D + A*                                                     eq. 1 
 
where D and A represent the donor and the acceptor molecules in a ground state, respectively 
and D* and A* represent the first excited state of the fluorophores.  
Since the excited acceptor can be converted into the ground vibrational level viavibrational 
relaxation, the inverse process is highly undesirable to occur. Consequently, the donor 
fluorophores arequenched while the acceptor fluorophores becomeexcited, giving a rise to 
the emission of a fluorescent light under appropriate conditions. 
The molecular processes underlying FRET are expounded in the Jablonski diagram (Figure 4.9). 
The theory that support the energy transfer is based on the concept of treating an excited 
chromophore as an oscillating dipole, which can undergo an exchange of energy with a second 
dipole containing identical resonance frequency.[184]As a result, FRET analysis can be 
employed as an efficient molecular ruler,  using a suitable donor and acceptor pair, for 






Figure 4.9: Jablonski diagram where  𝐾𝐹  is the rate constantof the donor fluorescence emission and  𝐾𝐷 is the 
sum of the rate constants of all other deexcitation processes of the donor.[185] 
 
In most cases, donor and acceptor are both fluorescent and the transfer of energy between 
them can be manifestedthrough quenching the fluorescence of the donor and reducing its 
fluorescence lifetime, accompanied byraising the fluorescence emission of the acceptor. 
According to Förster theory,[189] the rate of the energy transfer ( 𝐾𝑇) process varies in 
proportion with the sixth power of the distance separating donor and acceptor molecules (𝑅), 
given by the equation: 
 






6                                                           eq. 2 
 
where τD denotes the donor lifetime in the absence of the acceptor and 𝑅0 denotes the 
FÖRSTER or critical transfer distance between donor and acceptor when the transfer efficiency 
is 50%.[186,191,192] 
The efficiency of energy transfer (E) depends on the inverse sixth-distance between donor 
and acceptor (𝑅) devided by the FÖRSTER radius (𝑅0) under the condition of 1:1 situation of 
donor:acceptor concentrations, which is defined as follows: 
 









𝐸denotes the fraction of photons absorbed by the donor molecules that are transferred to 
the acceptor molecules. It is generallycalculated using the relative fluorescence intensity of 
the donor in presence (𝐹) and absence (𝐹0) of the acceptor:
[193] 
 
                                                                 𝐸 = 1 −  
𝐹
𝐹0
                                                                eq. 4 
 
Using the equations 3 and 4, the discrete distance 𝑅0 between the fluorophores can be then 
calculated as follows: 
 





6⁄                                                                  eq. 5 
 
Inside a lipid bilayer, the number of subunits in the peptide aggregate can be determined by 
using the dependence of the fluorescence of donor-labeled peptides on the mole fraction of 
acceptor-labeled peptides, according to a model defined by Adair and Engelman.[194] Hence, 
no energy transfer is expected in the absence of an assembly process.  This applied model was 
mainly based on four assumptions: labeling does not influence the association of the 
peptides,all peptides are located in the lipid bilayer,the interaction of the peptides is random, 
andone acceptor can quench all the donors within the same oligomer. 
The measured fluorescence at any titration point can be represented in the following way:[198] 
 
                                                          𝐹 =  𝑓𝐷(𝑁𝐷 − 𝑁𝑄) + 𝑓𝑄𝑁𝑄                                                   eq. 6 
 
where 𝑓𝐷represents the molar fluorescence of unquenched donor, 𝑓𝑄represents the molar 
fluorescence of quenched donor, 𝑁𝐷gives the total moles of donor and 𝑁𝑄gives the moles of 
quencheddonor. The value 𝑓𝑄depends mainly on the actual quenching of various 
labelingisomers in population of donor andacceptor oligomers and their distribution, which 
enables to determine the average of the entire population.[194] Thus, the fluorescence of the 




With a random number of donor and acceptor species in the oligomers, the relative 










                                                         q. 7 
 
Based on equations 6 and 7, the measured relative fluorescence 𝐹/𝐹0can be defined as the 
sum of the relative fluorescence of peptides in the monomeric state (𝐹/𝐹0)mand those in the 
oligomeric state (𝐹/𝐹0)o. 
 






















        eq. 9                     and                       𝑛0 =
𝑁0
𝑁𝑙𝑖𝑝𝑖𝑑
         eq. 10 
 
where 𝑁𝑚represents the number of peptides in the monomeric state, 𝑁0represents the total 
number of peptides and 𝑁𝑙𝑖𝑝𝑖𝑑represents the total number of lipid molecules.  
In addition, FRET can be statistically occurred in a vesicle without forming aggregates, which 
can be taken into account as has been described by Wolber and Hudson using the following 
approximation:[192] 
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𝐹
𝐹0








2)                              eq. 11 
 
where 𝐴1, 𝐴2, 𝐾1, and 𝐾2are constants,
[10]𝑅0is the FÖRSTER radius, 𝜒𝐴the mole fraction of the 
acceptor and 𝐴is the surface area of one vesicle, which is assumed to be 62.7 Å2 in the case of 




Accordingly, various association states can be conceivable using FRET experiments. In the case 
ofmonomer-dimer equilibrium, the equation 8 can be written as: 
 















)𝑑                                                  eq. 12 
 
with 
                                                       (
𝐹
𝐹0





)𝑑 is the relative fluorescence of peptides in the dimeric state. 
In the same way, in the case of monomer-trimer equilibrium, the equation 8 can be written 
as: 
 















)𝑡                                             eq. 14 
with 
 
                                                 (
𝐹
𝐹0
)𝑑 = 1 − 2𝜒𝐴 − 𝜒𝐴
2 = (1 − 𝜒𝐴)





)𝑡 is the relative fluorescence of peptides in the trimeric state. 
The dissociation constant 𝐾𝐷 can be defined as:
[196,197,199]  
 






                                                   eq. 16 
 
where 𝜒𝑃is the lipid-to-peptide ratio and 𝑛 is the number of species in the oligomer. The value 





4.3.2 Self-Assembly of Transmembrane β-Peptides 
The association state of fluorescently labeled β-peptides embedded in POPC LUVs at various 
peptide-to-lipid ratios and two different temperatures (20 °C and 60 °C) was addressed via 
FRET experiments. Thus, the dyes NBD and TAMRA were chosen as donor-acceptor pair and 
attached to the side chain of the last β3-Lys at the N-terminus of each β-peptide. These 
fluorophores have been successfully used to probe the oligomeric state of other peptides in 
membranes.[197,199,201] Furthermore, this pair is distinguished by a FÖRSTER radius ranging from 
5.1 - 5.5 nm depending on the composition of the lipid and the peptide.[177,196] Thus, in this 
study, the value 𝑅0 of this pair exceeds the inter-chromophore distance of all the synthesized 
β-peptides showing either 14- or 12-helical conformations expected for either parallel or anti-
parallel mode of association. Generally, self-assembly of transmembrane proteins should 
result in a decrease of NBD fluorescence with a concomitant increase of TAMRA 
fluorescence.[177,197] As previously described (see section 3.1), the β-sequences P0 and P5 were 
used as an initial model for designing other β-peptides bearing residues to impose helix-helix 
interactions and reinforce the formation of aggregates. Thus, these two sequences are 
expected to exist in a monomeric state within the membrane. To evaluate the 
thermodynamics of helix-helix association, FRET measurements were carried out at different 
peptide-to-lipid ratios by changing the concentration of POPC: 1:300 (1.65 mM POPC), 1:600 
(3.30 mM POPC), 1:900 (4.95 mM POPC), and 1:1200 (6.60 mM POPC). The samples were 
prepared separately with increasing concentration of TAMRA-labeled β-peptides (ranging 
from 0.00 to 2.75 μM) and keeping the concentration of NBD-labeled β-peptides constant at 
2.75 μM. The total concentration of the milieu was kept constant at 5.5 μM by adding the 
corresponding non-labeled β-peptides. The correction of spectra was achieved by subtracting 
each spectrum from its corresponding vesicle suspension without fluorescently labeled 
species. The data were obtained for each β-peptide by plotting the relative fluorescence 
(𝐹/𝐹0) of the donor in presence (𝐹) to that in absence (𝐹0) of the acceptor as a function of 
mole fraction of the quencher TAMRA-labeled peptide 𝜒𝐴. 
 
4.3.2.1 Self-Assembly of 14-Helices 
The possibleaggregation of β-peptides showing 14-helical secondary structure was addressed 
by measuring FRET experiments using the same conditions described previously. The results 















Figure 4.10: Relative emission of NBD-fluorescence (𝐹/𝐹0) as a function of 𝜒𝐴 for β-peptides showing 14-helix at 
1:300 (   ), 1:600 (   ), 1:900 (   ), 1:1200 (   ) peptide-to-lipid ratios and at 20 °C. For P0 (A) only statistical FRET was 
assumed (100 nm LUVs POPC, 𝑅0 = 5.1 nm). For P1(B), P2(C) and P3 (D) a monomer-dimer equilibrium was 
assumed and fitted to the obtained data as shown in different lines (solid black line for 1:300, dashed black line 
for 1:600, solid red line for 1:900 and dashed red line for 1:1200). 
 
In the case of P0, the data depicted in Figure 4.10A can be fitted to the theoretical formula of 
Wolber and Hudson[192]leading to a value of 𝑅0= 5.1 nm by assuming only statistical FRET. This 
value matches the one cited in the literature and supports our expectation that P0 exists as 
monomers in the membrane. For the three other β-peptides (P1, P2 and P3), the inclusion of 
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peptides by creating hydrogen bonds between the helices. In addition, the positions of β3-Gln 
amino acids within these β-peptides were organized to accomplish a symmetrical sequential 
arrangement of these helices in order to enable their association regardless of the parallel or 
anti-parallel mode of association. Thus, the preorganization of these sequences is expected to 
strongly favor the formation of oligomers in the membrane and more precisely the formation 




Figure 4.11: Schematic representation of self-dimerization of transmembrane 14-helices embedded in lipid 
bilayer composed of POPC. Red and blue positions in the β-peptides represent the positions of β3-Lys and β3-Trp, 
respectively whereas the black positions represent β3-Val functionalized with one, two and three β3-Gln (green 
positions) resulting the formation of P1, P2 and P3, respectively (left). Hydrogen bonding resulted from polar 
side chains of β3-Gln residues (right). 
 
The results of the FRET measurements forP1, P2 and P3 are shown in Figure 4.10B, C and D, 
respectively. Apparently, the data show an increase in quenching of the NBD-fluorescence 
over an increase of the concentration of the quencher TAMRA, which means that these β-
peptides tend to aggregate with strong affinity toward the number of β3-Gln residues.The best 
fit for FRET data was obtained by assuming a monomer-dimer model for all the β-peptides 
with dissociation constants (KD) of 0.0076 ± 0.002 MF for P1 (Figure 1B), 0.0034 ± 0.0002 MF 
for P2 (Figure 4.10C)and 0.0015 ± 0.0001 MF for P3 (Figure 4.10D). On the one hand, P2 with 
two β3-Gln and P3 with three β3-Gln emerge a full dimeric state as indicated by the good fit of 




4.10C and D). On the other hand, P1 with one β3-Gln does not fully self-associate in the 
membrane as expounded by the too small FRET effect at ratio of 1:300 (solid black line in 
Figure 4.10B).  
These overall results unequivocally prove that the polar β3-Gln residues have a significant 
effect on self-association properties of β-peptides with the concept that at least two β3-Gln 
are required within the helices to achieve a full-dimeric state. Recently, U. Rost from our group 
has investigated the possibility of aggregation in the case of asymmetrically introduced polar 
recognition units within β-peptides.[151] The results have shown that these helices tend to 
assemble into homo-trimers unlike the formation of homo-dimers presented in this study. In 
the fisrt case of study, U. Rost has invested the aggregational state of the β-peptides within 
the DOPC lipid bilayer which has a hydrocarbon thickness of 26.8 Å.[164] However, herein, the 
used POPC lipid system has a hydrocarbon thickness of 29.2 Å, [164] which means that the 
hydrophobic mismatch induced by the difference between the hydrocarbon region of the two 
lipid bilayers and the apolar part of the β-peptides adopting the 14-helix (which is 31.6 Å) is 
different in the both case of study. This variation indicates that the β-peptides have different 
tendency to associate within different models of lipid bilayers since the hydrophobic mismatch 
can significantly influence the formation of aggregates.[206] Therefore, this could be a possible 
explanation for the formation of dimers in this study rather than trimers that have been 
observed in the former case.  
It is expected that an increase in the temperature can break the hydrogen bond interactions 
between the helices and, thereby, nullify the dimeric character of P2 and P3. Thus, FRET 
experiments for these two β-peptides were performed at 60 °C while keeping other conditions 

































Figure 4.12: Relative emission of NBD-fluorescence (F/F0) as a function of χA for P2 (top) and P3 (bottom) at 60 °C 
and 1:300 ( ), 1:600 ( ), 1:900 ( ) and 1:1200 ( ) as peptide-to-lipid ratios. 
 
At 60 °C, P2 exhibits a complete segregation from dimers to monomers as presented in Figure 
4.12 (top). In contrast, P3did not fully dissociate by sustaining the dimeric character at ratio 
of 1:300 (Figure 4.12 bottom). These results suggest that P3 has greater propensity to form 
more rigiddimers due to the presence of a third β3-Gln, which means more interactions 
between the transmembrane helices.  
 
4.3.2.2 Self-Assembly of 12-Helices 
In the same way, analogical FRET studies were performed to gain insight into the prospect of 
self-association of β-peptides showing a 12-helical secondary structure. The obtained results 
are depicted in Figure 4.13. 
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Figure 4.13: Relative emission of NBD-fluorescence (𝐹/𝐹0) as a function of 𝜒𝐴for β-peptides showing 12-helix at 
1:300 (   ), 1:600 (   ), 1:900 (   ) peptide-to-lipid ratios and at 20 °C. For P5 only statistical FRET was assumed (100 
nm POPC LUVs with 𝑅0 = 5.1 nm). ForP6 (B), P7 (C) and P8 (D) a monomer-dimer equilibrium was assumed and 
fitted to the obtained data as shown in different lines (solid black line for 1:300, dashed black line for 1:600 and 
solid red line for 1:900). 
 
As it is the case for the 14-helix, the 12-helical conformation was systematically predesigned 
to achieve an orderly association of the sequences across the membrane by reconstituting the 
helices with one, two and three β3-Gln, respectively (see section 3.1). However, the possibility 
of these helices to form aggregates is limited by their mode of insertion into the membrane 
as well as the side chain alignments of their residues.  
Initially, P5 was structurally designed as an initial backbone without imposing any interaction 
that can cause self-assembly of the helices. Thus, it is expected to exist as monomers within 
the lipid bilayer. Figure 4.13A depicts the data obtained from measuring FRET analysis for P5 
in POPC at 20 °C and at different peptide-to-lipid ratios (same conditions as described 
previously). According to theoretical description of Wolber and Hudson, only statistical FRET 
measurement was assumed for P5 leading to a value of 𝑅0 = 5.1 nm.
[192] This value is in a good 
agreement with the literature and indicates that P5 was effectively found to be monomeric in 
the membrane.  
For P6, P7and P8, a monomer-dimer equilibrium was assumed and fitted to the FRET data as 
shown in figure 4.13B, C and D, respectively. The results clearly indicate that the monomer-
dimer model does not appropriately fit to the obtained FRET data in all cases. These findings 
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undoubtedly mean that there is no trend of these helices to form regular aggregates by 
exhibiting a very weak association relative to that of β-peptides showing 14-helix. 
Consequently, it could be a reflection that more likely random interactions occur between the 
helices. Since in this study the β3-Gln residues have been introduced based on the concept 
that the helices might self-associate in a parallel fashion, one plausible explanation could be 
that they prefer to associate in the membrane as anti-parallel bundles. This preference would 
constrain the interactions between the β3-Gln side chains in the case of β-peptides showing 
12-helix. To overcome this restriction, the positions of β3-Gln amino acids can be altered in 
order to achieve a direct contact between their side chains in the case of an anti-parallel 
orientation of the sequences.  
Another reason for the random interactions could be that the additional forces arising from 
β3-Gln side chains might not be sufficient to drive the 12-helices to self-assemble. Thus, the 
addition of more β3-Gln across the 12-helix can be a solution by creating more hydrogen bonds 
and thereby, increasing the possibility of interactions between the β-peptides. However, the 
addition of a large amount of these polar residues can lead to the binding of β-peptides on 
the membrane surface, which is certainly undesirable in this kind of study.  
 
4.3.3 Higher Order Aggregates of β-Peptides 
Designing a complex with a high molecular weight and suitable functional properties is of 
major interest in the field of biomacromolecular chemistry. Recently, self-assembly of 
subunits based on hydrogen bond interactions has considerably been studied.[207]  
It was shown that the selective introduction of β3-Gln residues within the helices has led to 
the homo-dimerization of the β-peptides showing 14-helix. These results are promising for 
further investigating whether these helices are able to show a complex inside the membrane 
with higher order aggregates. Thus, it is conceivable that the reasonable positioning of β3-Gln 
residues within the 14-helical backbone might drive the helices to show a well-defined self-
assembled complex. For this reason, the oligomer P4 was precisely designed by introducing 







Figure 4.14: Top view of the right-handed 14-helix P4distributed with two β3-Gln amino acids on two sides at 
different positions as indicated in the figure. 
 
The architecture of this peptide is expected to highly promote the formation of higher order 
aggregates by creating more non-covalent interactions between the polar side chains of the 
adjacent helices. 
To analyze self-assembly of P4 in LUVS composed of POPC, FRET experiments have been 
employed keeping the same conditions as previously described for other β-peptides (see 
section 4.3.2). Figure 4.15 illustrates the relative fluorescence of the NBD-labeled peptides 
(𝐹/𝐹0) plotted against the molar fraction of TAMRA-labeled species (𝜒𝐴). 
It is expected that in the case of the oligomer P4, the FRET data show a higher decrease in the 
NBD-fluorescence upon raising the concentration of TAMRA-labeled species than that 
resulted from the dimers P2 and P3. Indeed, the results depicted in Figure 4.15exhibita 
significant high FRET effect upon reaching equal concentrations of donor and acceptor species 
of approximately 72% (for 1:300 ratio), 60% (for 1:600 ratio) and 52% (for 1:900). This 
meansthat the extent of FRET between P4 oligomers is greater than that of all other β-




















Figure 4.15: Relative emission of NBD-fluorescence (𝐹/𝐹0) as a function of 𝜒𝐴 for P4 at 1:300 (   ), 1:600 (   ), 
1:900 (   ) peptide-to-lipid ratios and at 20 °C. The concentration of the NBD-labeled peptides was kept constant 
at 2.75 µM while varying the concentration of the TAMRA-labeled peptides from 0 µM to 2.75 µM. The 
concentration of the overall peptide was kept at 5.5 µM by adding the corresponding non-labeled peptides. 
 
This result suggests that P4 tends to form a higher order aggregates within the same complex.  
It is noteworthy that FRET experiments in this case are considered as a limited technique to 
define the exact number of subunits forming the complex, which renders this method more 
qualitative than quantitative. In this context, other methods such as ultra-centrifugation or 
fluorescence microscopy might assist to determine the accurate information concerning the 
order of the aggregates.  
 
4.3.4 Helix Orientation of Transmembrane β-Sequences within the Lipid Bilayer 
Themeasurement presented herein aimed at obtaining clearer perception of the structural 
adaptations of β-peptides inside the membraneby determining the mode of assembly of the 
membrane-associated aggregates. Thus, the fluorescence of NBD-labeled species within POPC 
liposomes was monitored.  
It is known that the fluorescence of NBD molecules can be self-quenched at higher 
concentrations.[200,201] Thus, in the case of a close contact between the N-termini of β-peptides 
as assumed in a parallel orientation, it is expected that the fluorescence of their NBD-labeled 




concentration of the NBD-probes. Otherwise, if the N-termini of β-peptides are far from each 
other as it is the case in an anti-parallel orientation, an increase in fluorescence of their NBD-
labeled analogues will be observed. Based on this concept, we examined the orientation mode 
of β-sequences P3 and P8 by the intensity of their fluorescently NBD-labeled analogues P3D 
and P8D, respectively, as a function of peptide mol% in POPC LUVs at 25 °C (Figure 4.16 and 
Figure 2.S in the “Appendix”).  
 































Figure 4.16: Fluorescence intensities of NBD-labeled β-peptides P3D (top) and P8D (bottom) defined as a function 





The data plotted in Figure 4.16 show a remarkable increase in the intensity of the NBD 
fluorescence upon increase of the concentration of fluorescent NBD-labeled analogues in both 
cases, P3D (Figure 4.16 top) and P8D (Figure 4.16 bottom) (see also Figure 2.S in the 
“Appendix”). These results mightily denote that no self-quenching has been occurred and 
therefore, the β-sequences P3 and P8 adopt anti-parallel strand orientation within the 
membrane.  
It is interesting to note that the characteristic of anti-parallel strand orientation has been also 
found for β-peptides functionalized with nucleobases in aqueous solution.[4,127] More 
generally, anti-parallel trends of adjacent helices are preferred over parallel trends in known 
structures of natural membrane proteins.[202,203] Thus, the present study might confirm that 
the non-natural β-peptides tend to assemble in anti-parallel strands, too, as has been found 
for biological proteins.One reasonable explanation for this anti-parallel association arises from 
the macro-dipole moment of the peptides. Although dipole-dipole interactions might be 
relatively weak, they are strong enough to orient the helices into an anti-parallel packing in 
the absence of stronger and/or specific helix association forces.[204-206] 
Overall, these findings might explain the reason of the random interactions that has been 
foundbetween the 12-helices, suggesting that they from anti-parallel aggregates within the 
membrane and that the side chains of the β3-Gln are far away from each other, which prevent 















Non-covalent interactions are thought to play a crucial role in many biological functions, such 
as enzyme catalysis, protein-protein and protein-nucleic acid binding.[1] Thus, specific 
physicochemical modifications of a given backbone can represent one approach to discern the 
roleof these non-covalent forcesin biological processes. However, the precise experimental 
delineation of chemical factors, which might control both the chemical selectivity and the 
biological reactivity remains difficult. Recently, designing peptidomimetics that adopt discrete 
tertiary structures and have the ability to penetrate the membrane is of great importance. In 
particular, β-peptides have been used as attractive model systems to mimic the biological 
functions of natural peptides. These non-natural polymers are characterized by rigid and well-
known helical conformations and they show the ability to remain stable towards enzymatic 
degradation.[2,109] 
In this study, the self-assembly of a novel series of β-peptidic helices that can specifically fold 
into 14- and 12-helices across membranes has been investigated. Thus, polar residues have 
been precisely introduced into the β-peptides to drive a regular arrangement of adjoining 
helices through non-covalent interactions. Initially, the design of these foldamers was based 
on the apparent malleability of β3-acyclic residues to adopt discrete conformations. In this 
regard, β-peptides containing a long sequence of either β3-Val or β3-Leu have been 
strategically synthesized to induce the formation of stable 14- and 12-helices, respectively. 
These sequences were further enriched by the presence of β3-Trp residues to maintain 
interactions with the interfacial region and to explore the position of proteins within the 
membrane. Moreover, the sequences were flanked by β3-Lys residues to enhance the 
solubility in aqueous media.  
β3-D-Amino acids derived from their natural D-amino acid counterparts have been successfully 
obtained via Arndt-Eistert homologation in very good yields. Worth mentioning, the synthesis 
of β-peptides containing a large amount of hydrophobic residues can be problematic, 
especially, after coupling the sixth amino acid. Therefore, a new synthetic methodology 
usingmanual microwave-assisted Fmoc-SPPS has been developedto successfully synthesize 





After the synthesis and purification, the helicity of the respective sequences has been 
characterizedusing CD spectroscopy. The data have shown the formation of a right-handed 
14-helix for β-peptides containing β3-Val residues and left-handed 12-helix for β-peptides 
containing β3-Leu residues. These two conformations are broadly described in the literature 
and used by several research groups, which suggest that they might be reasonable folding 
patterns for molecular recognition. Taking into account the differences between the structural 
backbones of the 14- and the 12-helices, the polar β3-Gln residues have been introduced in 
several positions across turns of the helices to create hydrogen bonds and thereby, to drive 
self-association of the β-peptides.  
To ensure the stability of the secondary structure of the sequences bearing β3-Gln residues, 
CD spectroscopy has been employed either in solution or within POPC liposomes. The results 
display that the β-peptidespreferably maintain their helicity, which demonstrate that the β3-
Gln units are well-tolerated in several positions along the helices.  
To confirm the insertion of β-peptides into the lipid bilayer, the intrinsic tryptophan 
fluorescence of β3-Trp amino acids inserted near the ends of the sequences was utilized. Thus, 
a blue-shift in the tryptophan fluorescence has been observed in all cases reflecting the 
presence of β3-Trp residues in the interface region of the membrane. Thereby, these findings 
signifythat the transmembrane β-peptides are existingwithin the membrane. 
In collaboration with Prof. Dr. Claudia Steinem, self-association of the β-peptides across 
membranes has been monitored by FRET analysis at various peptide-to-lipid ratios. In the case 
of β-peptides adopting 14-helix, FRET data have shown the formation of aggregates in a 
monomer-dimer equilibrium with strong affinity towards the number of β3-Gln residues. On 
the other hand, for β-peptides adopting 12-helixno clear trend to form regular aggregateswas 
observed, which indicate that a more random interhelical interactions occur. One reason for 
the random interactions could be that no sequential equilibrium was adjusted between the 
helices.  
The formation of homo dimers for β-peptides adopting 14-helix were promising for further 
investigate the possibility of designing higher-order assemblies. Thus, two sides of the 14-helix 
have been reconstituted with two β3-Gln molecules to form hydrogen bonds between more 
than two helices. The FRET data from measuring self-assembly of this oligomer indicated that 




observed in the case of dimers, while increasing the concentration of acceptor-labeled probes. 
These findings suggest the formation of higher order aggregates. 
In conclusion, β-peptides adopting either 14- or 12-helix were successfully synthesized and 
served as suitable scaffolds to organize a well-defined three-dimensional spatial arrangement 
of the helices within the membrane through hydrogen bonds. Especially, the 14-helices with 
three side chain alignments can be used as the most favorable scaffold to form defined 
aggregates. 
The assembly of transmembrane β-peptides can be further extended by inserting different 
recognitions units to the peptide backbone in order to reinforce the aggregation of the helices 
by various types of interactions likebase pairing or electrostatic interactions. The resulting β-
peptides bundles can lead to the formation of selective artificial transmembrane peptides with 
interesting biological functions, such as the formation of pore channels that play a crucial role 





6 Experimental Part 
6.1 General Synthetic Methods and Materials 
Solvents 
Technical solvents were distilled prior to use and other solvents of highest grade were 
available and were used without additional purification (EtOAc, pentane, MeOH, DCM, CHCl3, 
DMF, NMP, TFE, diethyl ether, acetonitrile). The solvents were obtained from Carl Roth Ltd, 
GL Biochem, Novabiochem, Alfa Aesar, Iris Biotech GmbH, Merck, VWR International Ltd, 
Sigma Aldrich and Fisher Scientific. Dry solvents were stored over molecular sieves of 4 Å. 
Piperidine was obtained from Riedel de Haen and used as supplied. For HPLC purification, 
MeOH was available as HPLC-grade and ultra-pure water (Mili-Q-H2O) was processed using a 
Simplicity system of Millipore (Bredford, UK). 
 
Reagents 
The protected amino acids, fluorophores, reagents and resins for solid phase peptide synthesis 
(SPPS) were purchased from Sigma Aldrich (Taufkirchen, Germany), Fluka (Taufkirchen, 
Germany), VWR International (Fontenay-sous-Bois, France), Grüssing GMBH (Filsum, 
Germany), ABCR (Karlsruhe, Germany), Merck (Darmstadt, Germany), Acros Organics (Geel, 
Belgium), Alfa Aesar (Karlsruhe, Germany), TCI (Zwijndrecht, Belgium), Applichem (Darmstadt, 
Germany), Fluorochem (Hadfield, UK), GL Biochem (Shanghai, China) and Carl Roth GMBH 
(Karlsruhe, Germany). Lipids were obtained from the Avanti Polar Lipids (Alabaster, USA), 
Bachem (Bubendorf, Germany) and Sigma Aldrich (St. Louis, USA). 
 
Reactions 
All reactions containing air- and moisture-sensitive reagents were carried out under an inert 
flow of argon gas. Glass equipment utilized for reactions under inert atmosphere was heated 
and dried under reduced pressure and flushed with argon prior to use. 
 
Lyophilization 
The peptides were freeze-drying using a Christ Alpha 2-4lyophilizer connected to a high 
vacuum pump. For small amounts in Eppendorf tubes an evaluable Christ RVC-18 centrifuge 





a. Thin layer chromatography (TLC)   
Analytical thin-layer chromatography (TLC) was performed on Merck silica gel 60 
F254aluminum plates. Detection was done under UV light at 254 nm or dipping into a solution 
of ninhydrin (2.0 g ninhydrin, 100 mL EtOH and 1 mL AcOH), KMnO4(1.0 g KMnO4, 6.75 g K2CO3, 
1.5 mL 5% aq. NaOH and 100 mL H2O) followed by heating using a heat-gun. 
 
b. Flash column chromatography : 
Flash column chromatography was performed using a Merck silica gel 60 (40 – 60 μm) under 
0.1-1 bar of pressure. All solid compounds were dissolved and absorbed to the fritted glass 
column filled with silica gel (50-100 times weight excess relative to the amount of the loaded 
substance).  
 
c. High performance liquid chromatography (HPLC): 
The peptides were purified using Amersham Pharmacia Biotech (Freiburg, Germany) (Äkta 
Basic 900, pump type P-900, UV/VIS Detector UV-900). The UV-absorption was detected at 
215 nm, 254 nm and 280 nm for non-labeled peptides. For NBD- or TAMRA-labeled peptides 
the UV-absorption was recorded at 460 nm or 550 nm respectively.[197]All crude samples were 
dissolved in MeOH/H2O and filtered prior to use. The columns used to purify the peptides 
were as follow: 
• Analytical HPLC: MN Nucleodur®(250 × 4.65 mm, C18, 100 Å, 5.0 μM).  
• Semi-preparative HPLC: MN Nucleodur®(250 × 10 mm, C18, 100 Å, 5.0 μM).  
• Preparative HPLC: MN Nucleodur®(250 × 20 mm, C18, 100 Å, 5.0 μM).  
Analytical HPLC was performed at flow rate of 1 ml/min, semi preparative HPLC at flow rate 
of 3 ml/min and preparative HPLC at flow rate of 10 ml/min. The solvents used for all the runs 
were: eluent A (water + 0.1%TFA) and eluent B (methanol + 0.1% TFA). The gradient of the 








Nuclear magnetic resonance spectroscopy (NMR) 
The 1H-NMR spectra were recorded at Varian Unity 300, Bruker AMX 300 or Varian INOVA 500 
NMR spectrometer. Chemical shifts δ were denoted in ppm with TMS as an internal standard 
(δTMS= 0 ppm) and referenced to the residual solvent peak of [D6] DMSO (1H: δ = 2.49 ppm). 
The multiplicities were classified by the following symbols: s (singlet), d (doublet), t (triplet), q 
(quadruplet), m (multiplet), br (broad signal). Coupling constants nJX,Y are in Hertz (Hz), where 
n is the order of coupling between atoms X and Y. 
 
Mass spectrometry (MS) 
Electrospray ionization mass spectra (ESI-MS) and high-resolution mass spectrometry (HRMS-
ESI) spectra were obtained with MicroTOF and maXis from Bruker devices (Karlsruhe, 
Germany). Other mass-spectrometric measurements (ESI) were carried out on LCQ mass 
spectrometer from Thermo Finnigan MAT (Waltham, USA). 
 
6.2.1 Analytical and Spectroscopic Methods 
UV/VIS spectroscopy 
Concentrations of stock solutions were measured using a Thermo Scientific NanoDrop 2000c 
spectrophotometer at 25 °C. Peptides concentration was calculated usingLambert–Beer’s law, 
given by: 
𝑪 =  
𝑨
𝜺 .  𝒍
 
Where 𝑪 is the concentration of the compound in solution (mol L-1) 
𝑨 is the absorbance (no units) 
𝜺 is the molar absorptivity (L mol-1 cm-1) 
𝒍 is the path length of the cuvette in which the sample is contained (cm) 
For unlabeled peptides, the molar absorptivity of a single tryptophan at 280 nm was used 
(ε280 = 5690 M-1 cm-1), while for labeled-peptides with TAMRA or NBD, the absorptions at 550 





Estimation of the loading density 
To determine the loading capacity of the loaded resin, UV/VIS-Spectrometer V-550 from Jasco 
(Gross-Umstadt, Germany) was used. Thus, 40 μM of DBU [1,8-diazabicyclo [5.4.0] undec-7-
en] and 2 ml of DMF were added to 5 mg of the dry loaded resin and gently shaken for 1-2 h. 
Thereafter, acetonitrile was added until 10 ml and the mixture was further diluted with 
acetonitrile (2/25) and transferred to an UV precision cuvette (1 cm x 1 cm). To estimate the 
loading capacity of the resin, the absorption of the dibenzofulven species was detected at 304 










𝜺 [𝑴−𝟏𝒄𝒎−𝟏] . 𝒅 [𝒄𝒎]
) . 𝟏𝟎𝟑 
 
Herewith, 𝝆(𝒓𝒆𝒔𝒊𝒏) is the loading density of the resin 
𝑨 the absorption 
𝑽 the volume of the graduated flask (here 1∙10-3 L)  
𝒇the thinning factor (here = 12.5) 
𝜺 the absorption coefficient of dibenzofulven  
𝒅 the path length of cuvette  
𝒎(𝒓𝒆𝒔𝒊𝒏) the mass of the analyzed resin  
 
Kaiser test[212] 
Kaiser test was also used to verify the successful coupling of the amino acids to the resin by 
determining the free amino groups. Thus, a few grains of the resin were placed into a small 
test tube and two drops of each of the following Kaiser test solutions were added to the resin: 
Solution 1: phenol in ethanol (80 g/20 mL). 
Solution 2: ninhydrin in ethanol (5 g/100 mL). 
Solution 3: aq. KCN (1 mM, 2 mL) in pyridine (98 mL). 
The resulting suspension was heated at 100 °C for 5 min. In the case of a positive test, a blue 
color appeared which means that there are free amino groups still on the resin. Otherwise, if 






Circular dichroism spectroscopy (CD) 
CD spectra were recorded on a Jasco-1500 spectropolarimeter equipped with a Julabo F250 
temperature controlling unit. Measurements were carried out in a 1 mm QS quartz cuvette 
(Suprasil® Hellma) at different temperatures and in a wavelength range of 190-300 nm with 
1.0 nm bandwidth using the 'continuous mode', 1.0 s response and 50 nm min-1 as a scan 
speed. A nitrogen flux was used to flash the sample cell at a flow rate of 3-5 L min-1. The 
measurements were carried out in organic solvent (MeOH, TFE) or vesicle suspensions 
containing 1:20 as P:L ratio in phosphate buffer (10 mM NaH2PO4 / Na2HPO4 buffer, pH = 7). 
The concentration of the peptides was adjusted to 30 μM and the temperature was recorded 
at 0 °C, 20 °C, 40 °C and 60 °C. Spectra were background-corrected against pure vesicle 
suspensions without incorporated peptides and the measurements were converted into molar 
ellipticity θ (deg cm2dmol-1).[211] 
 
6.2.2 Fluorescence Spectroscopy 
Förster resonance energy transfer (FRET) 
To measure FRET, different samples were prepared separately by keeping the concentration 
of the donor NBD-labeled peptides constant at 2.75 μM while varying the concentration of 
the acceptor TAMRA-labeled peptides from 0 to 2.75 μM (range of 0-0.5 μM). The total 
peptide concentration was maintained at 5.5 μM by using unlabeled peptides. The FRET 
measurements were performed at different peptide-to-lipid ratios by changing the lipid 
concentration: 1:300 (1.65 mM POPC), 1:600 (3.30 mM POPC), 1:900 (4.95 mM POPC) and 
1:1200 (6.60 mM POPC). All samples were prepared in phosphate buffer solution (10 mM, pH 
7) and the resulted FRET data were calculated as described previously in the 
literature.[192,194,199] For measuring FRET, fluorescence spectra were carried out on a JascoFP 
6200 fluorescence spectrometer (Gross-Umstadt, Germany) under temperature control using 
a Jasco-thermostat (Model ETC-272T, Groß-Umstadt, Germany). Fluorescence spectra were 
obtained by excitation at 465 nm with emission recorded in the wavelength range of 500-650 
nm at two different temperatures (20 °C and 60 °C). The excitation and the emission 
bandwidth were set to 3 nm, the data pitch was 1 nm and the response time was adjusted to 
0.2 s.Corrections for scattering were used by subtracting a spectrum of vesicles lacking 




fraction (χA) of the labeled-TAMRA peptides, the fluorescence intensity at 530 nm was 
displayed. 
 
Tryptophan fluorescence  
The tryptophan fluorescence of the β-peptides either in TFE or within large unilamellar 
vesicles composed of POPC (ratio of 1:600) was measured. Thus, the tryptophan fluorescence 
of β-peptides was excited at 280 nm and the fluorescence emission was detected in the range 
of 300-400 nm using a Jasco FP 6200 (Gros-Umstadt, Germany) under temperature control 
using a Jasco thermostat (model ETC-272T, Gros-Umstadt, Germany).  
 
6.3 Synthesis of β3-D-Amino Acids 
The β3-D-amino acids (β3-AA) used in this work were obtained from their corresponding α-




Scheme 6.1. Schematic presentation for the synthesis of β3-D-amino acids. 
 
Under argon atmosphere, the protected α-amino acid (1.0 eq.) was dissolved in dry THF and 
cooled to -21 °C, then triethylamine (1.10 eq.) and isobutyl chloroformate (1.10 eq.) were 
added and the mixture was stirred for 45 min. Under exclusion of light, the diazomethane (0.6-
0.7 M in diethyl ether, 2.00 eq.) was added to the solution and the mixture was warmed to 
room temperature (rt) and stirred for 5h. After stopping the reaction, 6% NaHCO3 (aq, 8.0 
mL/mmol) and acetic acid (0.03 eq.) were added to the mixture and extracted with EtOAc (3 
×). The combined organic phases were further washed with saturated NH4Cl (aq, 3 ×) and 




reduced pressure, the obtained diazoketone was used for the next step without further 
purification. 
As next step, the resulting product was dissolved in THF/H2O (9:1) and silver benzoate (0.10 
eq.) was added under exclusion of light. After 2 h of reaction in ultrasonic bath, the mixture 
was diluted with H2O and acidified with HCl (1 M) to pH ~ 2-3. After extracting with EtOAc (3 
×), the combined organic phases were dried over MgSO4 and the solvents were removed 
under reduced pressure. Finally, the obtained product was purified either using Flash column 
chromatography or by precipitation in cold pentane (Table 1).  
 
Table 6.3. Methods of purification of β3-D-amino acids. 
 
β3-D-Amino acids Yield in % Purification method 
Fmoc-β3-D-Lys(Boc)-OH (1) 80 
Flash chromatography 
DCM:MeOH (12:1) 
Fmoc-β3-D-Trp(Boc)-OH (2) 76 
Flash chromatography 
DCM:MeOH (24:1) 
Fmoc-β3-D-Val-OH (3) 90 
Precipitation in 
Pentane:DCM (10:1) 
Fmoc-β3-D-Gln(Trt)-OH (4) 72 
Flash chromatography 
DCM:MeOH (24:1) 
Fmoc-β3-D-Lys(Alloc)-OH (5) 80 
Flash chromatography 
DCM:MeOH (12:1) 




6.4 General Procedure for Solid Phase Peptide Synthesis (SPPS) 
Loading the resin with the first Fmoc-D-β3-AA 
The β-peptides were synthesized manually using a microwave-assisted Fmoc-solid phase 
peptide synthesis (SPPS), thus Discover microwave (MW) with reaction cavity (CEM) (Kamp-
Lintfort, Germany) was applied. The resins used in this study were as follow: rink amide MBHA 




rink amide resin LL with a loading capacity of 0.18 mmol/g (for the β-peptides containing β3-
Leu). To load the first β3-AA, the resin (1 eq., 0.1 mmol) was transferred into an acid/base 
resistant syringe equipped with a polyethylene filter from Becton-Dickinson BD-Discardit II 
(Heidelberg, Germany) and swollen in a mixture of DCM:NMP (1:1, 6 ml) for 1-2 h. After 
removing the solvents, deprotection of the Fmoc-protecting group was performed for the rink 
amide MBHA resin twice by adding 4 ml of 20% piperidine in NMP for 30 s and then for 3 min, 
50 °C and 25 W (NovaPEG rink amide resin does not have Fmoc-protecting group, see scheme 
1). Afterfiltration of the resin and washing with DMF (5 x), DCM (5 x) and NMP (5 x), the first 
coupling reaction was accomplished twice, using the same procedure for the two types of the 
resins, by adding a mixture containing the desired Fmoc-D-β3-AA (5 eq.), HOBt (5 eq.) and DIC 
(5 eq.) dissolved in 2 ml of NMP to the resin (20 min, 50 °C, 25 W). After washing the resin 
with DMF (3 x), DCM (3 x) and NMP (3 x), the second coupling was performed using a mixture 
containing the desired Fmoc-D-β3-AA (3 eq.), HOBt (3 eq.) and DIC (3 eq.) dissolved in 2 ml of 
NMP to the resin (20 min, 50 °C, 25 W). Finally, the resin was filtrated and washed with DMF 
(5 x), NMP (5 x), MeOH (10 x) and DCM (10 x) and dried overnight under vacuum. For each 
resin, the loading capacity was calculate as described previously.  
 
 
Scheme 6.2. chemical structure of NovaPEG rink amide resin (left) and MBHA rink amide resin (right). 
 
Synthesis cycle of the β-peptides using solid phase peptide synthesis (SPPS)  
• For rink amide MBHA resin: 
The synthesis cycle of β-peptides was continued by series of Fmoc-deprotection and β3-AA 
coupling procedures. Thus, the Fmoc-deprotection was achieved as described above and then 




eq.), HATU (4.5 eq., 2.7 eq.), HOAt (5 eq., 3 eq.) and DIPEA (10 eq., 2 x) dissolved in 2 ml of 
NMP (20 min, 50 °C, 25 W). The resin was washed between each step with DMF (3 x), DCM (3 
x) and NMP (3 x). After coupling the last β3-AA, Fmoc-deprotection was performed as 
described previously and the resin was washed with DMF (5x), NMP (5x), MeOH (10x) and 
DCM (10x) and dried under vacuum for the cleavage.  
 
• For NovaPEG rink amide LL resin: 
Due to the wide hydrophobicity of β-peptides containing β3-Leuamino acids, a third coupling 
was required, an addition of a stronger base (DBU) to remove the Fmoc-protecting group as 
well as an increase of the temperature to 75 °C during the coupling reaction. Thereby, after 
coupling the sixth amino acid as described above, the Fmoc-protecting group was removed 
using a mixture of 10% DBU, 10% piperidine in NMP twice for 3 min, 50 °C and 25 W. After 
washing the resin with DMF (3 x), DCM (3 x) and NMP (3 x), the next coupling was performed 
three times by adding the desired β3-AA (5 eq., 3 eq., 3 eq.), HATU (4.5 eq., 2.7 eq., 2.7 eq.), 
HOAt (5 eq., 3 eq., 3 eq.) and DIPEA (10 eq., 3 x) dissolved in 2 ml of NMP (20 min, 75 °C, 25 
W). Finally, after coupling the last β3-AA, Fmoc-deprotection was performed and the resin was 
washed with DMF (5 x), NMP (5 x), MeOH (10 x) and DCM (10 x) and dried under vacuum for 
the cleavage. 
 
Attaching the fluorophores to β-peptides 
FRET studies require an acceptor-donor pair, thus, the fluorophores 
carboxytetramethylrhodamine (TAMRA) as an acceptor and 4-chloro-7-nitrobenzo-2-oxa-1,3-
diazol (NBD-Cl) as a donor were selected in this work. The amino acids β3-Lys, β3-Trp and β3-
Gln were orthogonally protected to avoid side chain reactions. 
To attach the fluorophores to the β-peptides, the resins (5 μmol scale) were swollen in a 
mixture of DCM:NMP (1:1 6 ml) for 1-2h. After removing the solvents, (NBD-Cl) (50.0 μmol, 10 
eq., 200 mM) and DIPEA (100 μmol, 20 eq., 400 mM) dissolved in 750 μL of NMP or 
respectively TAMRA (42.5 μmol, 8.5 eq., 170 mM), PyBop (40 μmol, 8 eq., 160 mM) and DIPEA 
(100 μmol, 20 eq., 400 mM) dissolved in 750 μL of NMP were added. The mixtures were 
shaken overnight under exclusion from light. Subsequently, the resins were filtrated and 





Cleavage of β-peptides from the resin:  
β-Peptides were cleaved from the resin by adding 10 ml of a cocktail containing 95% TFA, 2.5% 
H2O and 2.5% TIS. After 2 h of stirring at room temperature, the cleaved peptides were 
filtrated into a small plastic tube and concentrated under a nitrogen-stream. Finally, the crude 
peptide was isolated by precipitation from cold diethyl ether at -20 °C and dried under vacuum 
for further purification. 
 
6.5 Preparation of Peptide/Lipid Vesicles 
6.5.1 Multilamellar Vesicles (MLVs) 
The lipids 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) or 1,2-dilauroyl-sn-
glycero-3-phosphocholine (DLPC) were dissolved in CHCl3 and β-peptides were dissolved in 
TFE and mixed together with different peptide-to-lipid (P:L) ratios. At temperature (T) above 
the gel-to-fluid transition temperature of the lipids(Tm) which is -2 °C for POPC and ~ -1 °C for 
DLPC,[164] the solvents were evaporated under a stream of nitrogen followed by several hours 
in vacuum to obtain clear peptide–lipid films. The latter were rehydrated with an appropriate 
amount of phosphate buffer solution (10 mM, pH 7) and let incubate for 1 h. Keeping always 
T>Tm, the suspension was vortexed several times for 30 seconds with subsequent incubation 
for 5 min (5 cycles). 
 
6.5.2 Large Unilamellar Vesicles (LUVs) 
To obtain large unillamelar vesicles (LUVs), the milky suspensions of MLVs were extruded 31 
times through a 100 nm nominal pore size polycarbonate membrane using a mini extruder 
from Liposofast (Avestin, Ottawa, Canada) to produce a clear vesicle suspension containing 
LUVs of 100 nm size. 
 
Fluorescence quenching analysis 
To quench the fluorescence of NBD molecules, the reducing dithionite ions (S2O42-) dissolved 
in phosphate buffer solution (10 mM, pH 7) were externally added to LUVs containing NBD-




containing 5.5 μM NBD-labeled peptides (1:600 as P:L ratio) were treated with freshly 
prepared dithionite ions (100 μM) and the time course of NBD fluorescence was monitored 
for 20 min using an excitation and an emission wavelengths of 450 nm and 533 nm, 
respectively.[178] 
 
6.6 Analytical Data 
6.6.1 β3-D-Amino Acids 
All the following β3-D-amino acids have been synthesized through Arndt–Eistert 
homologation from their α-D-amino acids counterparts (see section 6.3). The purification was 
performed for each β3-D-amino acid either using Flash column chromatography or by 











1H-NMR (300 MHz, [D6]DMSO): δ (ppm) = 1.13-1.47 (m, 15 H, 3 × CH3, 3 × CH2), 2.27-2.41 (m, 
2 H, 2 α-CH2), 2.81-2.91 (m, 2 H, CH2), 3.69-3.82 (m, 1 H, β-CH), 4.14-4.32 (m, 3 H, Fmoc- CH2, 
Fmoc-CH), 6.69 (s, 1 H, NH), 7.17 (d, 1 H, 3JH,H = 8.7 Hz, NH), 7.28-7.36 (m, 2 H, 2 × Fmoc-CH), 
7.42 (t, 3JH,H = 7.4 Hz, 2 H, 2×Fmoc-CH), 7.69 (d, 2 H, 3JH,H = 7.5 Hz, 2 × Fmoc-CH), 7.88 (d, 3JH,H 




ESI-MSm/z (%) = 987.5 [2M+Na]+, 505.3 [M+Na]+, 483.3 [M+H]+. 
HR-MS (ESI): calculated for 483.2490 [M+H]+, 505.2309 [M+Na]+, 481.2344 [M-H]-; found 





butanoic acid (2) 
 




1H-NMR (300 MHz, [D6]DMSO): δ (ppm) = 1.58 - 1.66 (m, 9 H, 3 × CH3), 2.42-2.52 (m, 2 H, CH2), 
2.86 (d, 2 H, 3JH,H = 6.7 Hz, α-CH2), 4.09-4.24 (m, 4 H, Fmoc-CH2, Fmoc-CH, β-CH), 7.19-7.43 (m, 
8 H, 4 × Fmoc-CH, NH, 3 × Trp-H), 7.54-7.64 (m, 2 H, 2 × Fmoc-CH), 7.69 (d, 3JH,H = 7.2 Hz, 1 H, 
Trp-H), 7.86 (d, 3JH,H = 7.2 Hz, 2 H, 2 × Fmoc-CH), 8.04 (d, 3JH,H = 7.6 Hz, 1 H, Trp-H), 12.1 (sbr, 1 
H, COOH).  
ESI-MSm/z (%) = 541.3 [M+H]+, 558.3 [M+NH4]+, 563.2 [M+Na]+. 
HR-MS (ESI): calculated for 541.2333 [M+H]+, 563.2153 [M+Na]+, 558.2599 [M+NH4]+; found 








(R)-3-((9H-fluoren-9-yl)-methoxy-carbonyl-amino)-4-methyl-pentanoic acid (3) 
 




1H-NMR (300 MHz, [D6]DMSO): δ (ppm) = 0.70-0.88 (m, 6 H, 2 × CH3), 1.68-1.80 (m, 1 H, CH), 
2.26-2.46 (m, 2 H, α-CH2), 3.68-3.82 (m, 1 H, β-CH), 4.18-4.37 (m, 3 H, Fmoc-CH, Fmoc-CH2), 
7.20 (d, 1 H, 3JH,H = 8.1 Hz, NH), 7.28-7.46 (m, 4 H, 4 × Fmoc-CH), 7.68-7-78 (m, 2 H, 2 × Fmoc-
CH), 7.88 (d, 2 H, 3JH,H = 6.6 Hz, 2 × Fmoc-CH), 12.2 (sbr, 1 H, COOH). 
ESI-MSm/z (%) = 354.2 [M+H]+, 376.2 [M+ Na]+, 392.1 [M+K]+, 729.3 [2M+Na]+, 745.3 [2M+K]+. 
HR-MS (ESI): calculated for 354.1700 [M+H]+, 376.1519 [M+Na]+, 392.1259 [M+K]+ 352.1554 




(R)-3-((9H-fluoren-9-yl)-methoxy-carbonyl-amino)-6-oxo-6-(tritylamino) hexanoic acid (4) 
 







1H-NMR (300 MHz, [D6]DMSO): δ (ppm) = 1.50-1.74 (m, 2 H, α-CH2), 2.22-2.39 (m, 4 H, 2 CH2), 
3.78-3.90 (m, 1 H, β-CH), 4.20-4.34 (m, 3 H, Fmoc-CH, Fmoc-CH2), 7.17-7.46 (m, 20 H, 3 × C5H5, 
NH, 4 × Fmoc-CH), 7.70 (d, 2 H, 3JH,H = 7.3 Hz, 2 × Fmoc-CH), 7.90 (d, 2 H, 3JH,H= 7.8 Hz, 2 × 
Fmoc- CH), 8.50 (s, 1 H, NH), 12.2 (sbr, 1 H, COOH). 
ESI-MSm/z (%) = 623.3.2 [M-H]-, 625.3 [M+H]+, 647.3 [M+ Na]+, 1271.5 [2M+Na]+. 
HR-MS (ESI): calculated for 625.2697 [M+H]+, 674.2516 [M+Na]+, 623.2551 [M-H]-; found 




(R)-3-((9-fluoren-9-yl)-methoxy-carbonyl-amino)-7-(Allyloxy-carbonyl-amino) heptanoic acid 
(5) 
 




1H-NMR (300 MHz, [D6]DMSO): δ (ppm) = 1.14-1.50 (m, 6 H, 3 CH2), 2.23-2.44 (m, 1 H, CH2), 
2.91-3.02 (m, 2 H, α-CH2), 3.70-3.84 (m, 1 H, β-CH), 4.16-4.37 (m, 3 H, Fmoc-CH, Fmoc-CH2), 
4.40-4.50 (m, 2 H, Alloc-CH2), 5.11-5.32 (m, 2 H, 2 Alloc-CH), 5.90 (ddt, 1 H, 3JH,H = 15.2, 9.6, 
5.1 Hz, Alloc-CH), 7.06-7.20 (m, 2 H, 2 × NH), 7.28-7.43 (m, 4 H, 4 × Fmoc-CH), 7.70 (d, 2 H, 3JH,H 
= 6.7 Hz, 2 × Fmoc-CH), 7.90 (d, 2 H, 3JH,H = 6.7 Hz, 2 × Fmoc-CH), 12.2 (sbr, 1 H, COOH). 




HR-MS (ESI): calculated for 467.2177 [M+H]+, 489.1996 [M+Na]+, 465.2031 [M-H]-; found 











1H-NMR (300 MHz, [D6]DMSO): δ (ppm) = 1.17-1.42 (m, 15 H, 3 × CH3, 2 CH2), 2.22- 2.39 (m, 
2 H, CH2), 2.91-3.01 (m, 2 H, α-CH2), 3.65-3.76 (m, 1 H, β-CH), 4.17-4.33 (m, 3 H, Fmoc-CH, 
Fmoc- CH2), 6.60 (d, 1 H, 3JH,H = 8.6 Hz, NH), 7.21 (t, 1 H, 3JH,H = 5.8 Hz, NH), 7.28-7.43 (m, 4 H, 
4 × Fmoc-CH), 7.68 (d, 2 H, 3JH,H = 7.4 Hz, 2 × Fmoc-CH), 7.89 (d, 2 H, 3JH,H = 7.1 Hz, 2 × Fmoc-
CH), 12.2 (sbr, 1 H, COOH). 
ESI-MSm/z (%): 483.3 [M+H]+, 505.3 [M+Na]+, 521.2 [M+K]+, 987.5 [2M+Na]+. 








6.6.2 Synthesized β-Peptides 
All the following β-peptides have been synthesized by manual microwave-assisted Fmoc-
SPPS(see section 6.4), purified by HPLC using a C18 reversed-phase column,and characterized 
by mass spectrometry. Attaching the fluorophores to the β-peptides has been performed on 




C190H316N36O27 [3534,45 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 60 min, λ: 215, 254, 280 nm) tR = 41.7 min. 
ESI-MSm/z (%): 708.3 [M+5H]5+, 885.1 [M+4H]4+, 1179.8 [M+3H]3+.  
HR-MS (ESI): calculated for [M+3H]3+: 1179.8246, [M+4H]4+: 885.1203, [M+5H]5+: 708.2977; 




C203H331N41O31 [3839,56 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 50 min, λ: 215, 460, 280 nm) tR = 39.7 min.  




HR-MS (ESI): calculated for [M+2H]2+: 1921.7895, [M+3H]3+: 1281.5288, [M+4H]4+: 961.3984, 
[M+5H]5+: 769.3202; found [M+2H]2+: 1921.7890, [M+3H]3+: 1281.5296, [M+4H]4+:961.3975, 




C222H350N40O32 [4088.70 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 50 min, λ: 215, 550, 280) tR = 35 min.  
ESI-MSm/z (%): 682.8 [M+6H]6+, 819.1 [M+5H]5+, 1023.7 [M+4H]4+, 1364.6 [M+3H]3+. 
 
HR-MS (ESI): calculated for [M+3H]3+: 1364.5756, [M+4H]4+: 1023.6835, [M+5H]5+: 819.1483, 
[M+6H]6+: 682.7915; found [M+3H]3+: 1364.5762, [M+4H]4+:1023.6849, [M+5H]5+: 819.1483, 
[M+6H]6+: 682.7917. 
 
6.6.2.4 P0U: H-hLys3-hTrp2-hVal19-hTrp2-hLys2-NH2 
 
C197H330N38O28 [3676.56 g/mol] 
 
HPLC:(Gradient: 80-100% B in 60 min, λ: 215, 254, 280 nm) tR = 37.3 min.  





HR-MS (ESI): calculated for [M+2H]2+: 1840.2886, [M+3H]3+: 1227.1948, [M+4H]4+: 920.6479, 
[M+5H]5+: 736.7198,[M+6H]6+: 614.1011;found [M+2H]2+: 1840.2871, [M+3H]3+:1227.1959, 
[M+4H]4+: 920.6487, [M+5H]5+: 736.7204, [M+6H]6+: 614.1011. 
 
6.6.2.5 P1: H-hLys2-hTrp2-hVal9-hGln-hVal9-hTrp2-hLys2-NH2 
 
C190H315N37O28 [3563.44 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 60 min, λ: 215, 254, 280 nm) tR = 45.3 min.  
ESI-MSm/z (%): 714.1 [M+5H]5+, 892.4 [M+4H]4+, 1189.5 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1189.4880, [M+4H]4+:892. 3678, [M+5H]5+: 714.0957; 
found [M+3H]3+: 1189.4888, [M+4H]4+:892.3682, [M+5H]5+: 714.0959. 
 
6.6.2.6 P1D: H-hLys(NBD)-hLys2-hTrp2-hVal9-hGln-hVal9-hTrp2-hLys2-NH2  
 
C203H330N42O32 [3871.14 g/mol] 
 
 
HPLC:(Gradient: 70-100% B in 60 min, λ: 215, 460, 280 nm) tR = 38.2 min.  





HR-MS (ESI): calculated for [M+3H]3+: 1291.1963, [M+4H]4+: 968.6431, [M+5H]5+: 775.1160; 
found [M+3H]3+: 1291.1861, [M+4H]4+: 968.6454, [M+5H]5+: 775.1159. 
 
6.6.2.7 P1A: H-hLys(TAMRA)-hLys2-hTrp2-hVal9-hGln-hVal9-hTrp2-hLys2-NH2  
 
C222H349N41O33 [4117.69 g/mol] 
 
 
HPLC:(Gradient: 70-100% B in 60 min, λ: 215, 550, 280 nm) tR = 34.5 min.  
ESI-MSm/z (%): 687.6 [M+6H]6+, 825.0 [M+5H]5+, 1374.3 [M+3H]3+. 
 
HR-MS (ESI): calculated for [M+5H]5+: 824.9488, [M+6H]6+: 687.6252; found [M+5H]5+: 
824.9472, [M+6H]6+: 687.6232. 
 
6.6.2.8 P1U: H-hLys3-hTrp2-hVal9-hGln-hVal9-hTrp2-hLys2-NH2  
 
C197H329N39O29 [3705.55 g/mol] 
 
 
HPLC:(Gradient: 70-100% B in 60 min, λ: 215, 254, 280 nm) tR = 43.8 min.  




HR-MS (ESI): calculated for [M+3H]3+: 1236.8582, [M+4H]4+: 927.8955, [M+5H]5+: 742.5178, 
[M+6H]6+: 618.9321; found [M+3H]3+: 1236.8598, [M+4H]4+: 927.8954, [M+5H]5+: 742.5187, 
[M+6H]6+: 618.9320. 
 
6.6.2.9 P2: H-hLys2-hTrp2-hVal3-hGln-hVal11-hGln-hVal3-hTrp2-hLys2-NH2 
 
C190H314N38O29 [3592.43 g/mol] 
 
 
HPLC:(Gradient: 70-100% B in 60 min, λ: 215, 254, 280 nm) tR = 48.1 min.  
ESI-MSm/z (%): 719.5 [M+5H]5+, 899.1 [M+4H]4+, 1198.4 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1198.4755, [M+4H]4+: 899.1066, [M+5H]5+: 719.4853; 
found [M+3H]3+: 1198.4827, [M+4H]4+: 899.1139, [M+5H]5+: 719.4926. 
 
6.6.2.10 P2D: H-hLys(NBD)-hLys2-hTrp2-hVal3-hGln-hVal11-hGln-hVal3-hTrp2-hLys2-NH2  
 
C203H329N43O33 [3868.55 g/mol] 
 
HPLC:(Gradient: 70-100% B in 60 min, λ: 215, 460, 280 nm) tR = 36.1 min.  




HR-MS (ESI): calculated for [M+3H]3+: 1300.8555, [M+4H]4+: 975.8935, [M+5H]5+: 780.9162, 
[M+6H]6+: 650.9314; found [M+3H]3+: 1300.8571, [M+4H]4+: 975.8943, [M+5H]5+: 780.9168, 
[M+6H]6+: 650.9314. 
 
6.6.2.11 P2A: H-hLys(TAMRA)-hLys2-hTrp2-hVal3-hGln-hVal11-hGln-hVal3-hTrp2-hLys2-NH2 
 




HPLC:(Gradient: 70-100% B in 60 min, λ: 215, 550, 280 nm) tR = 31.6 min.  
ESI-MSm/z (%): 692.5 [M+6H]6+, 830.7 [M+5H]5+, 1038.2 [M+4H]4+, 1383.9 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1383.9024, [M+4H]4+: 1038.1786, [M+5H]5+: 830.7443, 
[M+6H]6+: 692.4548; found [M+3H]3+: 1383.9037, [M+4H]4+: 1038.1795, [M+5H]5+: 830.7448, 
[M+6H]6+: 692.4546. 
 
6.6.2.12 P2U: H-hLys3-hTrp2-hVal3-hGln-hVal11-hGln-hVal3-hTrp2-hLys2-NH2  
 
C197H328N40O30 [3734.54 g/mol] 
 
 
HPLC:(Gradient: 70-100% B in 60 min, λ: 215, 254, 280 nm) tR = 44 min.  




HR-MS (ESI): calculated for [M+3H]3+: 1246.5216, [M+4H]4+: 935.1430, [M+5H]5+: 748.3159, 
[M+6H]6+: 623.7644; found [M+3H]3+: 1246.5235, [M+4H]4+: 935.1443, [M+5H]5+: 748.3166, 
[M+6H]6+: 623.7647. 
 






HPLC:(Gradient: 70-100% B in 60 min, λ: 215, 254, 280 nm) tR = 48.7 min.  
ESI-MSm/z (%): 725.3 [M+5H]5+, 906.3 [M+4H]4+, 1203.1 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1203.1389, [M+4H]4+: 906.3542, [M+5H]5+: 725.2833; 








HPLC:(Gradient: 70-100% B in 60 min, λ: 215, 460, 280 nm) tR = 35.5 min.  




HR-MS (ESI): calculated for [M+3H]3+: 1310.5189, [M+4H]4+: 983.1410, [M+5H]5+: 786.7143, 









HPLC:(Gradient: 70-100% B in 60 min, λ: 215, 460, 280 nm) tR = 33.8 min.  
ESI-MSm/z (%): 597.8 [M+7H]7+, 697.3 [M+6H]6+, 7836.5 [M+5H]5+, 1045.4 [M+4H]4+, 1393.6 
[M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1393.5658, [M+4H]4+: 1045.4261, [M+5H]5+: 836.5424, 
[M+6H]6+: 697.2865, [M+7H]7+: 597.8181; found [M+3H]3+: 1393.5669, [M+4H]4+: 1045.4270, 
[M+5H]5+: 836.5432, [M+6H]6+: 697.2868, [M+7H]7+: 597.8176. 
  
6.6.2.16 P3U: H-hLys3-hTrp2-hVal3-hGln-hVal5-hGln-hVal5-hGln-hVal3-hTrp2-hLys2-NH2  
 
C197H327N41O31 [3763.53 g/mol] 
 
 




ESI-MSm/z (%): 628.6 [M+6H]6+, 754.1 [M+5H]5+, 942.4 [M+4H]4+, 1256.2 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1256.1850, [M+4H]4+: 942.3906, [M+5H]5+: 754.1139, 










HPLC:(Gradient: 70-100% B in 70 min, λ: 215, 254, 280 nm) tR = 34.5 min.  
ESI-MSm/z (%): 628.6 [M+5H]5+, 754.1 [M+4H]4+, 942.4 [M+3H]3+, 1872.2[M+2H]2+. 
HR-MS (ESI): calculated for [M+2H]2+: 1827.2136, [M+3H]3+: 1218.4782, [M+4H]4+: 914.1104, 






C203H327N45O35 [3955.52 g/mol] 
 
 




ESI-MSm/z (%): 792.5 [M+5H]5+, 990.4 [M+4H]4+, 1320.2 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1320.1823, [M+4H]4+: 990.3885, [M+5H]5+: 792.5123; 





C222H346N44O36 [4204.66 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 70 min, λ: 215, 550, 280 nm) tR = 25.1 min.  
ESI-MSm/z (%): 702.1 [M+6H]6+, 842.3 [M+5H]5+, 1052.6 [M+4H]4+, 1403.2 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1403.2292, [M+4H]4+: 1052.6737, [M+5H]5+: 842.3404, 














ESI-MSm/z (%): 759.9 [M+5H]5+, 949.6 [M+4H]4+, 1265.8 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1265.8484, [M+4H]4+: 949.6381, [M+5H]5+: 759.9119; 
found [M+3H]3+: 1265.8438, [M+4H]4+: 949.6394, [M+5H]5+: 759.9113. 
 
6.6.2.21 P5: H-hLys2-hTrp2-hLeu15-hTrp2-hLys2-NH2  
 
C181H302N32O23 [3292.34 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 70 min, λ: 215, 254, 280 nm) tR = 41.6 min.  
ESI-MSm/z (%): 759.9 [M+5H]5+, 949.6 [M+4H]4+, 1265.8 [M+3H]3+, 1655.6 [M+2H]2+. 
HR-MS (ESI): calculated for [M+2H]2+: 1648.1828,[M+3H]3+: 1099.1243, [M+4H]4+: 824.5951, 
[M+5H]5+: 659.8775; found [M+2H]2+: 1648.1827, [M+3H]3+: 1099.1246, [M+4H]4+: 824.5950, 
[M+5H]5+: 659.8770. 
 
6.6.2.22 P5D: H-hLys(NBD)-hLys2-hTrp2-hLeu15-hTrp2-hLys2-NH2  
 
C194H317N37O27 [3597.46 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 60 min, λ: 215, 460, 280 nm) tR = 27.5 min.  




HR-MS (ESI): calculated for [M+4H]4+: 900.8730, [M+5H]5+: 720.8999; found [M+4H]4+: 
900.8729, [M+5H]5+: 720.8998. 
 
6.6.2.23 P5A: H-hLys(TAMRA)-hLys2-hTrp2-hLeu15-hTrp2-hLys2-NH2  
 
C213H336N36O28 [3846.61 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 60 min, λ: 215, 550, 280 nm) tR = 25 min.  
ESI-MSm/z (%): 642.4 [M+6H]6+, 770.7 [M+5H]5+, 963.1 [M+4H]4+, 1283.8 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1283.8751, [M+4H]4+: 963.1582, [M+5H]5+: 770.7280, 
[M+6H]6+: 642.4412; found [M+3H]3+: 1283.8765, [M+4H]4+: 963.1577, [M+5H]5+: 770.7286, 
[M+6H]6+: 642.4416. 
 
6.6.2.24 P5U: H-hLys3-hTrp2-hLeu15-hTrp2-hLys2-NH2  
 
C188H316N34O24 [3434.46 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 70 min, λ: 215, 254, 280 nm) tR = 30.7 min.  
ESI-MSm/z (%): 759.9 [M+5H]5+, 949.6 [M+4H]4+, 1265.8 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1146.4944, [M+4H]4+: 860.1226, [M+5H]5+: 688.2995; 





6.6.2.25 P6: H-hLys2-hTrp2-hLeu7-hGln-hLeu7-hTrp2-hLys2-NH2  
 
C180H299N33O24 [3307.32 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 60 min, λ: 215, 254, 280 nm) tR = 29.1 min.  
ESI-MSm/z (%): 759.9 [M+5H]5+, 949.6 [M+4H]4+, 1265.8 [M+3H]3+, 1655.6 [M+2H]2+. 
HR-MS (ESI): calculated for [M+2H]2+: 1655.6701,[M+3H]3+: 1104.1158, [M+4H]4+: 828.3387, 
[M+5H]5+: 662.8724; found [M+2H]2+: 1655.6692, [M+3H]3+: 1104.1166, [M+4H]4+: 828.3388, 
[M+5H]5+: 662.8718. 
 
6.6.2.26 P6D: H-hLys(NBD)-hLys2-hTrp2-hLeu7-hGln-hLeu7-hTrp2-hLys2-NH2  
 
C193H314N38O28 [3612.43 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 40 min, λ: 215, 460, 280 nm) tR = 18  min.  
ESI-MSm/z (%): 723.9 [M+5H]5+, 904.6 [M+4H]4+, 1205.8 [M+3H]3+, 1808.2 [M+2H]2+. 
HR-MS (ESI): calculated for [M+2H]2+: 1808.2260,[M+3H]3+: 1205.8198, [M+4H]4+: 904.6166, 







6.6.2.27 P6A: H-hLys(TAMRA)-hLys2-hTrp2-hLeu7-hGln-hLeu7-hTrp2-hLys2-NH2  
 
C112H333N37O29 [3861.57 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 40 min, λ: 215, 550, 280 nm) tR = 13.3 min.  
ESI-MSm/z (%): 773.7 [M+5H]5+, 966.9 [M+4H]4+, 1288.8 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1288.8666, [M+4H]4+: 966.9018, [M+5H]5+: 773.7229; 
found [M+3H]3+: 1288.8698, [M+4H]4+: 966.9023, [M+5H]5+: 773.7233. 
 
6.6.2.28 P6U: H-hLys3-hTrp2-hLeu7-hGln-hLeu7-hTrp2-hLys2-NH2  
 
C187H313N35O25 [3449.43 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 60 min, λ: 215, 254, 280 nm) tR = 21.7 min.  
ESI-MSm/z (%): 773.7 [M+5H]5+, 966.9 [M+4H]4+, 1288.8 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1151.4859, [M+4H]4+: 863.8662, [M+5H]5+: 691.2944; 







6.6.2.29 P7: H-hLys2-hTrp2-hLeu3-hGln-hLeu4-hGln-hLeu6-hTrp2-hLys2-NH2  
 
C179H296N34O25 [3322.29 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 50 min, λ: 215, 254, 280 nm) tR = 26.1 min.  
ESI-MSm/z (%): 665.8 [M+5H]5+, 832.1 [M+4H]4+, 1109.1 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1109.1073, [M+4H]4+: 832.0823, [M+5H]5+: 665.8673; 
found [M+3H]3+: 1109.1078, [M+4H]4+: 832.0816, [M+5H]5+: 665.8666. 
 
6.6.2.30 P7D: H-hLys(NBD)-hLys2-hTrp2-hLeu3-hGln-hLeu4-hGln-hLeu6-hTrp2-hLys2-NH2  
 
C192H311N39O29 [3627.41 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 50 min, λ: 215, 460, 280 nm) tR = 22.5 min.  
ESI-MSm/z (%): 726.9 [M+5H]5+, 908.3 [M+4H]4+, 1210.8 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1210.8113, [M+4H]4+: 908.3603, [M+5H]5+: 726.8897; 






6.6.2.31 P7A: H-hLys(TAMRA)-hLys2-hTrp2-hLeu3-hGln-hLeu4-hGln-hLeu6-hTrp2-hLys2-NH2  
 
C211H330N38O30 [3876.54 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 50 min, λ: 215, 550, 280 nm) tR = 20.7 min.  
ESI-MSm/z (%): 776.7 [M+5H]5+, 970.6 [M+4H]4+, 1293.8 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1293.8581, [M+4H]4+: 970.6454, [M+5H]5+: 776.7178; 
found [M+3H]3+: 1293.8557, [M+4H]4+: 970.6447, [M+5H]5+: 776.7213. 
 
6.6.2.32 P7U: H-hLys3-hTrp2-hLeu3-hGln-hLeu4-hGln-hLeu6-hTrp2-hLys2-NH2  
 
C186H310N36O26 [3464.40 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 60 min, λ: 215, 254, 280 nm) tR = 41.7 min.  
ESI-MSm/z (%): 694.3 [M+5H]5+, 867.6 [M+4H]4+, 1156.4 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1156.4773, [M+4H]4+: 867.6098, [M+5H]5+: 694.3; found 







6.6.2.33 P8: H-hLys2-hTrp2-hLeu3-hGln-hLeu4-hGln-hLeu4-hGln-hLeu1-hTrp2-hLys2-NH2  
 
C178H293N35O26 [3337.26 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 50 min, λ: 215, 254, 280 nm) tR = 36.7 min.  
ESI-MSm/z (%): 835.8 [M+4H]4+, 1114.1 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1114.0988, [M+4H]4+: 835.8259; found [M+3H]3+: 





C191H308N40O30 [3642.38 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 50 min, λ: 215, 460, 280 nm) tR = 30.5 min.  
ESI-MSm/z (%): 729.8 [M+5H]5+, 912.1 [M+4H]4+, 1215.8 [M+3H]3+, 1823.2 [M+2H]2+. 
HR-MS (ESI): calculated for [M+2H]2+: 1823.2005, [M+3H]3+: 1215.8028, [M+4H]4+: 912.1039, 











C210H327N39O31 [3891.52 g/mol] 
 
 
HPLC:(Gradient: 80-100% B in 40 min, λ: 215, 254, 280 nm) tR = 28.3 min.  
ESI-MSm/z (%): 779.7 [M+5H]5+, 974.4 [M+4H]4+, 1298.8 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1298.8496, [M+4H]4+: 974.3890, [M+5H]5+: 779.7127; 
found [M+3H]3+: 1298.8496, [M+4H]4+: 974.3890, [M+5H]5+: 779.7133. 
 
6.6.2.36 P8U: H-hLys3-hTrp2-hLeu3-hGln-hLeu4-hGln-hLeu4-hGln-hLeu1-hTrp2-hLys2-NH2  
 




HPLC:(Gradient: 80-100% B in 50 min, λ: 215, 254, 280 nm) tR = 32.5 min.  
ESI-MSm/z (%): 697.3 [M+5H]5+, 871.3 [M+4H]4+, 1161.4 [M+3H]3+. 
HR-MS (ESI): calculated for [M+3H]3+: 1161.4690, [M+4H]4+: 871.3536, [M+5H]5+: 697.2843; 








CD spectra of β-peptides P1 - P4 (containing β3-Val) and β-peptides P6 – P8 (containing β3-
Leu) in TFE at 60 °C. 
 


























































Figure 1.S. (A) CD spectra of β-peptides showing right-handed 14-helix (P1, P2, P3 and P4) and 
(B) β-peptides showing left-handed 12-helix (P6, P7 and P8) in TFE at 60 °C and concentration 







Helix Orientation of Transmembrane β-peptides P3 and P8 within POPC LUVs. 
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Figure 2.S. NBD-Fluorescence intensity defined as emission peak area in the range of 490-650 










Insertion of transmembrane β-peptidesP1 - P4 (containing β3-Val) and β-peptides P6 – P8 
(containing β3-Leu) within the membrane. 
 
             in POPC                in TFE 
 























































































































Figure 3.S. β3-Trp fluorescence spectra of P1 (A), P2 (B), P3 (C), P4 (D), P6 (E), P7 (F) and P8 (G) 
within the lipid bilayer POPC LUVs using 1:600 as peptide-to-lipid ratio as well as in TFE at 


























Topological insertion of transmembrane β-peptides P1 - P4 (containing β3-Val) and β-peptides 
P6-P8 (containing β3-Leu) into the lipid bilayer 
 































































Figure 4.S. External addition of sodium dithionite solution to POPC LUVs containing 0.16 mol% 
fluorescent NBD-labeled P3D (A), P4D (B) and P8D (C). Fluorescence signal and excitation 











Concentration dependent fluorescence spectra of transmembrane β-peptides P0 - P4 
(containing β3-Val) and β-peptides P5-P8 (containing β3-Leu) at various peptide-to lipid ratios 
and at two different temperatures as indicated in the corresponding figure.  
 
P0χA =             0             0.1              0.2             0.3            0.4             0.5 














1:300 at 20 °C
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P3χA =             0             0.1              0.2             0.3            0.4             0.5 
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Figure 5.S. Fluorescence emission spectra of NBD-labeled species for different peptide-to-lipid ratio 
and at temperature as indicated in the respective figure. The concentration of NBD-labeled peptides 
(donor) was kept constant at 2.75 μM while varying the concentration of TAMRA-labeled peptides 
(acceptor) from 0.00 χA to 0.50 χA mole fraction. The overall β-peptides concentration was kept 





Å   angstrom (10-8cm) 
AcOH  acetic acid 
Alloc   allyloxycarbonyl  
aq  aqueous 
Boc   tert-butoxycarbonyl  
°C   degree Celsius 
CD   circular dichroism  
δ  chemical shift  
d   dublet 
DBU   1,8-diazabicyclo[5.4.0]undec-7-en  
DCM   dichlormethane  
DIC   N,Nˈ-diisopropylcarbodiimide  
DIPEA   N,N-diisopropylethylamine  
DLPC  1,2-dilauroyl-sn-glycero-3-phosphocholine 
DMF   N,N-dimethylformamide  
DMSO   dimethyl sulfoxide  
eq.  equivalent  
ESI   electrospray-ionisation  
EtOAc  ethyl acetate 
Fmoc   fluorenylmethoxycarbonyl  
FRET   förster resonance energy transfer  
HATU   O-(7-azabenzotriazol-1-yl)-N,N,Nˈ,Nˈ-tetramethyluronium 
hexafluorophosphate  
HBTU   O-(1H-benzotriazol-1-yl)-N,N,Nˈ,Nˈ-tetramethyluronium hexafluorophosphate  
HOAt   1-hydroxy-7-azabenzotriazole  
HOBt   1-hydroxybenzotriazole  
HPLC   high performance liquid chromatography  
HR-MS  high resolution mass spectrometry  
LUV   large unilamellar vesicle  




M   molar 
MBHA   4-methylbenzhydrylamine 
MeOH  methanol 
MF   mole fraction  
MLV  Multilamellar Vesicles 
m/z   ratio of mass to charge 
NBD   7-nitrobenz-2-oxa-1,3-diazol-4-yl  
NMP   N-methyl-pyrrolidone  
NMR   nuclear magnetic resonance  
P:L   peptide-to-lipid  
POPC  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
pH   the negative logarithm hydrogen-ion activity (−log10[H3O+]) 
ppm   parts per million  
PyBOP  benzotriazole-1-yl-oxy-tris-pyrrolodino-phosphonium hexafluorophosphate  
rt   room temperature  
SPPS   solid phase peptide synthesis  
SUV   small unilamellar vesicle  
TAMRA  5(6)-carboxytetramethylrhodamine  
TFA   trifluoroacetic acid  
TFE   trifluoroethanol  
THF   tetrahydrofuran  
TLC   thin-layer chromatography 
TIS   triisopropylsilan  
TMS   trimethylsilan  
tR  retention time 
Trt   trityl  
UV   ultraviolet  
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